

CURRICULUM VITAE

Rebecca A. Hubbard, PhD

Address: Department of Biostatistics
Brown University School of Public Health
Box G-S121-7
121 South Main Street
Providence, RI 02912

E-mail: rebecca_hubbard@brown.edu

Web page: <https://sites.brown.edu/regardslab/>

EDUCATION

2007 PhD, Biostatistics, University of Washington, Seattle, WA
2002 MSc, Applied Statistics, with Honors, Oxford University, Oxford, UK
2001 MSc, Epidemiology, University of Edinburgh, Edinburgh, UK
1999 BS, Ecology & Evolution, Summa Cum Laude, University of Pittsburgh, Pittsburgh, PA

ACADEMIC APPOINTMENTS

2024 – Present Professor of Biostatistics and Data Science, Brown University School of Public Health
2024 – Present Carl Kawaja and Wendy Holcombe Professor of Public Health, Brown University School of Public Health
2024 – Present Member, Legoretta Cancer Center, Brown University
2024 – Present Adjunct Professor, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania
2025 Acting Chair, Department of Biostatistics, Brown University School of Public Health
2022 – 2024 Vice Chair for Faculty Professional Development, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania
2020 – 2024 Member, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
2020 – 2022 Deputy Director, Division of Biostatistics, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania
2020 – 2024 Professor, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania
2018 – 2024 Senior Fellow, Institute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania
2014 – 2024 Senior Scholar, Center for Clinical Epidemiology & Biostatistics, Perelman School of Medicine, University of Pennsylvania
2009 – 2014 Affiliate Assistant Professor, Department of Biostatistics, University of Washington
2014 – 2020 Associate Professor, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania

2014 – 2017 Affiliate Associate Professor, Department of Biostatistics, University of Washington

OTHER EMPLOYMENT

2013 – 2014 Associate Investigator, Group Health Research Institute

2008 – 2013 Assistant Investigator, Group Health Research Institute

2007 – 2008 Senior Fellow, National Alzheimer’s Coordinating Center, University of Washington

2002 – 2007 Graduate Research Assistant, Department of Biostatistics, University of Washington

AWARDS AND HONORS

2024 Research Excellence Award, ASA Philadelphia Chapter

2023 Gertrude M. Cox Award, Washington Statistical Society

2021 Jane M. Glick Graduate Student Teaching Award, Perelman School of Medicine, University of Pennsylvania

2020 American Statistical Association Health Policy Statistics Section Mid-Career Award

2019 Samuel L. Martin Health Evaluation Sciences Award, University of Pennsylvania

2019 Excellence in Teaching Award, Master of Science in Health Policy Research Program, University of Pennsylvania

2019 Fellow, American Statistical Association

2019 Penn Fellow, University of Pennsylvania

2008 David P. Byar Young Investigator Award, Biometrics Section of the American Statistical Association, Joint Statistical Meetings, Denver, CO

2007 Best Paper, Western North American Region (WNAR) of the International Biometric Society Student Paper Competition, Irvine, CA

2007 Best Oral Presentation, Western North American Region (WNAR) of the International Biometric Society Student Paper Competition, Irvine, CA

2007 Outstanding Student Award, University of Washington Department of Biostatistics

2006 – 2007 Magnuson Scholar, University of Washington School of Public Health

2004 Donovan J. Thompson Award, University of Washington Department of Biostatistics

2000 – 2002 Marshall Scholar

1999 Phi Beta Kappa

PROFESSIONAL ORGANIZATIONS

2005 – Present Member, American Statistical Association

2005 – Present Member, International Biometric Society

PROFESSIONAL ACTIVITIES

International

Reviewer Dutch Cancer Society, 2012, 2015

Netherlands Organisation for Scientific Research, 2015, 2019

Canadian Institute for Health Research SPOR Innovative Clinical Trials, 2017, 2019

French National Cancer Institute, 2018

Conferences	Scientific Organizing Committee, International Conference on Health Policy Statistics, 2018
Editorial	Editorial Advisory Committee, International Biometric Society, 2018 – 2024 Editor-in-chief, Biostatistics, 2023 – Present
National	
Leadership	Chair-elect (2017), Chair (2018), Past Chair (2019), American Statistical Association Biometrics Section Council of Sections Representative to the Board of Directors, American Statistical Association, 2020 – 2022 Chair, Elizabeth L. Scott Award Selection Committee, Committee of Presidents of Statistical Societies, 2021 – 2022 Chair, Committee of Presidents of Statistical Societies, 2025 – Present Co-Chair, International Conference on Health Policy Statistics, Health Policy Statistics Section, American Statistical Association, 2025 – Present
Reviewer	NIH Resource Centers for Minority Aging Research Special Emphasis Panel, 2012 Cancer Research Network Research Scholars Program, 2014 PCORI Assessment of Prevention, Treatment, and Diagnosis Options panel, 2014 NIH Health Services Organization and Delivery Study Section <i>Ad Hoc Reviewer</i> , 2014, 2016, 2018 NIH Healthcare Delivery and Methodologies Member Conflicts Special Emphasis Panel, 2015 – 2017 NIH Health Services Research on Minority Health and Health Disparities Special Emphasis Panel, 2016 PCORI Improving Methods for Conducting PCOR Review Panel, 2018, 2026 NCI Clinical and Translational Exploratory/Developmental Studies Special Emphasis Panel, 2018 NCI Biostatistics Branch Site Visit Team, 2018 NIH Biomedical Computing and Health Informatics Member Conflicts Special Emphasis Panel, 2019 NIH Community Influences on Health Behavior Study Section <i>Ad Hoc Reviewer</i> , 2020 NIH Interdisciplinary Clinical Care in Specialty Care Settings Study Section, Standing Panel Member, 2021 – 2025 PCORI Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research panel, 2026
Conferences	Program committee, JSM (WNAR representative), 2010 – 2011 Program committee, JSM (Biometrics section representative), 2013 – 2015 Program committee, ENAR (ASA Health Policy Statistics Section Representative), 2018
Committees	Panelist, NIH Pathways to Prevention: Total Worker Health, 2015 Byar Award Selection Committee, American Statistical Association Biometrics Section 2015 – 2019

Committee on Care Interventions for Individuals with Dementia and Their Caregivers, National Academies of Science, Engineering, and Medicine, 2018

Elizabeth L. Scott Award Selection Committee, Committee of Presidents of Statistical Societies, 2019 – 2021

Committee on Scientific Freedom and Human Rights, American Statistical Association, 2019 – 2022

Committee on Applied and Theoretical Statistics, National Academies of Science, Engineering, and Medicine, 2021 – Present

Executive Committee for Oncology Quality Characteristics and Assessment of Real-world Data (QCARD) Initiative, Reagan-Udall Foundation for the FDA, 2021 – 2023

Committee on Review of Evidence on Alcohol and Health, National Academies of Science, Engineering, and Medicine, 2023 – 2024

Editor Search Committee, Journal of the American Statistical Association: Applications and Case Studies, 2024.

DSMB

Systematic Multidomain Alzheimer's Risk Reduction Trial, 2018 – 2021

Editorial

Associate Editor, Pharmacoepidemiology & Drug Safety, 2017 – 2021

Editorial Board, Journal of Clinical Oncology 2020 – 2022

Associate Editor, Observational Studies, 2021 – 2022

Statistical Editor, New England Journal of Medicine, 2021 – Present

Associate Editor, Statistics in Medicine, 2021 – 2022

Associate Editor, Journal of the American Statistical Association: Applications and Case Studies, 2022 – Present

Brown University

Leadership

Chair, Faculty search committee, Department of Biostatistics and Data Science Institute, 2025

Committees

Faculty search committee, Department of Health Services, Policy & Practice, 2024

Faculty search committee, Legoretta Cancer Center and Department of Biostatistics, 2024

Masters' Admissions Committee, Department of Biostatistics, 2024

Awards committee, Department of Biostatistics, 2025 – present

Research committee, Department of Biostatistics, 2025 – present

Operations committee, Department of Biostatistics, 2025 – 2026

Marshall Scholarship Review Committee, 2025 – present

University of Pennsylvania

Leadership

Chair, Academic Advising & Review Committee, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, 2017-2020

Executive Committee, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, 2018-2022

Leadership Advisory Council, Department of Biostatistics, Epidemiology & Informatics, 2019-2020

Chair, Faculty Recruitment Committee, Biostatistics Division, Department of Biostatistics, Epidemiology & Informatics, 2019-2023

Executive Committee, Center for Pharmacoepidemiology Research & Training, Department of Biostatistics, Epidemiology & Informatics, 2021-2024

Chair, Health Evaluation Sciences Awards Committee, Perelman School of Medicine, 2021-2023

Committees

Admissions Committee, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, 2015-2017

Examinations Committee, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, 2016-2018

Awards Committee, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, 2016-2018

Faculty Recruitment Committee, Biostatistics Division, Department of Biostatistics, Epidemiology & Informatics, 2016-2019

Biostatistics Division Director Recruitment Committee, Biostatistics Division, Department of Biostatistics & Epidemiology, 2017-2019

Vice Provost for Education's Fellowship Selection Committee, 2018-2021

Health Evaluation Sciences Awards Committee, Perelman School of Medicine, 2020

Faculty Senate Committee on Academic Freedom and Responsibility, 2021-2024

Epidemiology Division Director Recruitment Committee, Epidemiology Division, Department of Biostatistics & Epidemiology, 2021-2022

Curriculum Committee, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, 2021-2024

IT Council, Perelman School of Medicine, 2021-2022

Institute for Biomedical Informatics, Director Search Committee, Perelman School of Medicine, 2021

Department of Medical Ethics and Health Policy Chair Search Committee, Perelman School of Medicine, 2021-2022

University of Washington

Leadership Chair, Affiliate and Adjunct Faculty Committee, Department of Biostatistics, 2009-2012
Chair, Applied Statistics Qualifying Exam Committee, Department of Biostatistics, 2013-2014

Committees Applied Statistics Qualifying Exam Committee, Department of Biostatistics, 2012
Distinguished Alumni Selection Committee, School of Public Health, 2012-2014
Admissions Committee, Department of Biostatistics, 2013

Group Health Research Institute

Leadership Chair, Scientific Policy Committee, 2010-2012

Committees New faculty Orientation Committee, 2009

Data Governance Council, 2012-2014

Scientific Policy Committee, 2013-2014

DIVERSITY, EQUITY AND INCLUSION ACTIVITIES

Chair and Head Judge, Section on Physical and Quantitative Sciences, Annual Biomedical Research Conference for Minority Students, 2010 – 2012.

Diversity Search Advisor, Biostatistics Division, Department of Biostatistics, Epidemiology & Informatics, 2016 – 2022.

Mentor, JSM Diversity Mentoring Program, American Statistical Association, 2018 – Present.

Member, Combatting Racial Inequities Committee, Biomedical Graduate Studies, Perelman School of Medicine, University of Pennsylvania, 2020-2021.

Presenter, Memorial Sloan Kettering Cancer Center, Bridge2Biostat, July 2021.

Chair, ASA Board of Director's Task Force on Increasing Diversity in Editorial Positions, 2021.

Presenter, Quantitative Approaches to Understand Diseases with Electronic Health Record Data, Society for Advancement of Chicanos/Hispanics and Native Americans in Science, October 2021.

Workgroup Leader, African Diaspora Joint Working Group (ADJOINT) Program, Mathematical Sciences Research Institute, 2022 – 2023.

TEACHING ACTIVITIES

Courses

BIOST 571: Statistical Methodology: Regression Models for Dependent Data, Department of Biostatistics, University of Washington, Graduate Teaching Assistant, Winter 2005.

BIOST 511: Medical Biometry I, Department of Biostatistics, University of Washington, Graduate Teaching Assistant, Summer 2006, Summer 2007.

Linear Regression and ANOVA, Summer Institute in Statistical Genetics. Department of Biostatistics, University of Washington, Course Director, Summer 2009 – Summer 2023.

BIOST 579: Data Analysis and Report Writing, Department of Biostatistics, University of Washington, Course Director, Spring 2011, Summer 2013.

HPR 608: Applied Regression Analysis for Health Policy Research, Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Course Director, Spring 2016, Spring 2018, Spring 2019.

EPID 600: Data Science for Biomedical Informatics, Department of Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Guest Lecturer, Fall 2016, Fall 2017, Fall 2018.

Introduction to Grant Writing, Graduate Group in Epidemiology & Biostatistics, Perelman School of Medicine, University of Pennsylvania, Course Director, Summer 2017, Summer 2018, Fall 2019.

Bayesian Methods for Clinical Research - Introduction, Summer Institute in Statistics for Clinical Research. Department of Biostatistics, University of Washington, Course Director, July 2017.

Bayesian Methods for Clinical Research - Computation and Applications, Summer Institute in Statistics for Clinical Research. Department of Biostatistics, University of Washington, Course Director, July 2017.

Biostatistical Concepts in Pharmacoepidemiology: Linear and Logistic Regression, Food and Drug Administration, Instructor, December 2016, December 2018, December 2019,

December 2020.

Practical Solutions for Working with Electronic Health Records Data, ENAR Short Course, March 2020.

Analysis of Big Healthcare Databases, ASA Council of Chapters Traveling Short Course, Instructor, ASA Nebraska Chapter April 2019, ASA Princeton/Trenton Chapter September 2019, ASA Connecticut Chapter October 2019, ASA Twin Cities Chapter October 2019, ASA San Francisco Chapter November 2019, University of California Davis November 2019, ASA Kentucky Chapter October 2020, ASA Cincinnati Chapter October 2020, ASA Philadelphia Chapter November 2020, ASA Houston Area Chapter December 2020.

BSTA 660: Design of Observational Studies, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Course Director, Spring 2018, Fall 2019, Fall 2020, Fall 2021, Fall 2022, Fall 2023.

Case Studies in Generating Real World Evidence from Real World Data, ENAR Short Course, March 2021.

PHP 2605: Generalized Linear Models, Department of Biostatistics, Brown University School of Public Health, Course Director, Spring 2026

MS Students

Victoria Ding, 2011 – 2012, MS thesis supervisor, Department of Biostatistics, University of Washington.

Jian Hu, 2017 – 2018, MS thesis supervisor, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Joanna Harton, 2017 – 2018, MS thesis supervisor, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Shuyan Luo, 2025 – 2026, MS thesis supervisor, Department of Biostatistics, Brown University School of Public Health

Mengyue Liu, 2025 – 2026, MS thesis supervisor, Department of Biostatistics, Brown University School of Public Health

Nathan Cai, 2026 – present, MS thesis supervisor, Department of Biostatistics, Brown University School of Public Health

Yifei Feng, 2026 – present, MS thesis supervisor, Department of Biostatistics, Brown University School of Public Health

Urmi Ghosh, 2026 – present, MPH thesis supervisor, Brown University School of Public Health

PhD Students

Amy Laird, 2010 – 2013, Member PhD committee, Department of Biostatistics, University of Washington.

Jane Lange, 2011 – 2014, Member PhD committee, Department of Biostatistics, University of Washington.

Greg Calip, 2013 – 2014, Member PhD committee, Department of Epidemiology, University of Washington.

Willa Brenowitz, 2013 – 2016, Member PhD committee, Department of Epidemiology, University of Washington.

Lu Chen, 2015, Member PhD committee, Department of Biostatistics & Epidemiology, University of Pennsylvania

Lu Wang, 2016 – 2019, Chair PhD committee, Department of Biostatistics &

Epidemiology, University of Pennsylvania

Darcy Ellis, 2016 – 2021, Chair PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Marzieh Golmakani, 2017 – 2019, Member PhD committee, Department of Public Health Sciences, UC Davis

Lingjiao Zhang, 2018 – 2020, Member PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Sondra Lavigne, 2018 – 2020, Chair PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Sherrie Xie, 2018 – 2021, Member PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Joanna Harton, 2018 – 2022, PhD Co-Supervisor (with Nandita Mitra), Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Arielle Anglin, 2020 – 2021, Chair PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Jiayi Tong, 2021 – 2024, Chair PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Jenny Shen, 2021 – 2024, PhD Co-Supervisor (with Kristin Linn), Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Danielle Kellier, 2022 – 2024, Member PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Dane Isenberg, 2023 – 2026, Member PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Sarah Hegarty, 2023 – 2026, Member PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Chunnan Liu, 2024 – present, PhD Co-Supervisor (with Joseph Hogan), Department of Biostatistics, Brown University School of Public Health

Tiffany Hsieh, 2024 – present, PhD Co-Supervisor (with Sarah Ackley), Department of Epidemiology, Brown University School of Public Health

Meghan Gerety, 2026 – present, Member PhD committee, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Post-doctoral

Yue Zhang, 2012 – 2013, Post-doctoral fellowship supervisor, Group Health Research Institute

Jane Lange, 2014, Post-doctoral fellowship supervisor, Group Health Research Institute

Noah Hoffman, 2015 – 2016, MSHP Biostatistics advisor, Department of Biostatistics & Epidemiology, University of Pennsylvania

Therese Bittermann, 2015 – 2017, MSCE Biostatistics advisor, Department of Biostatistics & Epidemiology, University of Pennsylvania

Gary Weissman, 2016 – 2017, MSHP Biostatistics advisor, Department of Biostatistics & Epidemiology, University of Pennsylvania

Juan Lado, 2016 – 2017, MSHP Biostatistics advisor, Department of Biostatistics & Epidemiology, University of Pennsylvania

Krisda Chaiyachati, 2016 – 2018, MSHP Biostatistics advisor, Department of

Biostatistics & Epidemiology, University of Pennsylvania

Megan Noe, 2015 – 2018, MSCE Biostatistics advisor, Department of Biostatistics & Epidemiology, University of Pennsylvania

Sherif Elhanafi, 2016 – 2018, MSCE Biostatistics advisor, Department of Biostatistics & Epidemiology, University of Pennsylvania

Whitney Cabey, 2016 – 2018, MSHP Biostatistics advisor, Department of Biostatistics & Epidemiology, University of Pennsylvania

Joanna Rhodes, 2018 – 2019, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Nadim Mahmud, 2018 – 2019, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Natasha Vedage, 2018 – 2020, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Lova Sun, 2019 – 2021, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Shun Yu, 2019 – 2021, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Mohsin Shah, 2019 – 2021, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Daniel Vader, 2020 – 2022, Post-doctoral fellowship supervisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Hilary Whitworth, 2020 – 2023, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Nicole Ferrante, 2021 – 2023, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Jeffrey Shevach, 2021 – 2023, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Hanxi (Molly) Zhang, 2022 – 2023, Post-doctoral fellowship supervisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Chenxi (Chelsea) Yuan, 2022 – 2024, Post-doctoral fellowship supervisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Ernesto Ulloa-Perez, 2022 – 2024, Post-doctoral fellowship supervisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Jacob Reibel, 2023 – 2025, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Pedro Ochoa-Allemant, 2023 – 2025, MSCE Biostatistics advisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Melanie Mayer, 2024 – Present, Post-doctoral fellowship supervisor, Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania

Kenya Andrews, 2025 – Present, Post-doctoral fellowship supervisor, Department of Biostatistics, Brown University

Other advising Elisa Sheng, 2009 – 2013, Academic advisor, Department of Biostatistics, University of Washington.

Dana Canfield, 2010, Summer undergraduate internship supervisor, Group Health Research Institute.

Willa Brenowitz, 2011, Summer MPH practicum supervisor, Department of Health Services, University of Washington.

David Benkeser, 2014, Graduate research assistantship supervisor, Department of Biostatistics, University of Washington.

LaNae Schaal, 2014, Summer independent study supervisor, Department of Biostatistics, University of Washington.

Le Wang, 2015, Biostatistics in Practice II supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Carrie Caswell, Fall 2015, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Carrie Caswell, 2015 – 2016, Academic advisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Rui Duan, 2016, Biostatistics in Practice II supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Grace Choi, Fall 2016, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Joanna Milton, Fall 2016, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Arman Oganisian, Spring 2016, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Victoria Arthur, 2016 – 2017, Academic advisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Grace Choi, Summer 2017, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Carolyn Lou, Spring 2018, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Lanair Lett, Spring 2019, Fall 2019, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Emily Getzen, 2019 – 2021, Academic advisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Kylie Getz, Spring 2020 - Spring 2021, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Jevaughn Henry, Summer 2020, Mentor, American Physician Scientist Association Virtual Summer Research Program

Melissa Martin, Fall 2021, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Yuqing Lei, Fall 2023, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Meghan Gerety, Spring 2024, Lab rotation supervisor, Biostatistics Program, Graduate Group in Epidemiology & Biostatistics, University of Pennsylvania

Jina Yang, 2025, RA supervisor, Department of Biostatistics, Brown University School

of Public Health

Adam Kurth, 2026 – present, Academic advisor, Department of Biostatistics, Brown University School of Public Health

Shuqi He, 2026 – present, Academic advisor, Department of Biostatistics, Brown University School of Public Health

RESEARCH PROGRAM

Present Funding as PI

R01 HL162354 (MPI: Himes/Hubbard) NHLBI Precision Approaches to Reduce Asthma Disparities with Electronic Health Record Data	09/01/2022-06/30/2026 Role: MPI	10%
P01 CA154292 (PI: Miglioretti/Kerlikowske/Tosteson) NCI Advancing Equitable Risk-based Breast Cancer Screening and Surveillance in Community Practice	09/16/2022-05/31/2027 Role: Site PI	15%
N/A (PI: Hubbard) Brown University Data Science Institute Data Science Collaborative for Real World Evidence in Cancer Therapeutics	01/01/2026-06/30/2027 Role: PI	0%

Past Funding as PI

R21 AG075574 (MPI: Linn/Hubbard) NIA Informatics Methods for Leveraging Clinical Data Sources to Study Risk Factors for Alzheimer's Disease	02/15/2022-01/31/2024 Role: MPI	10%
R21 CA227613 (PI: Hubbard) NCI Improving Confounder Control in EHR-based Studies of Cancer Epidemiology	01/01/2019-12/31/2021 Role: PI	10%
ME-1511-32666 (PI: Hubbard) PCORI Statistical Methods for Phenotype Estimation and Analysis Using Electronic Health Records	09/01/2016-08/31/2020 Role: PI	20%
R03 CA182986 (PI: Hubbard) NCI Statistical Methods for Estimation of Benefits & Harms of Repeat Cancer Screening	01/01/2014-12/31/2016 Role: PI	20%
261201100031C (PI: Hubbard) NCI Breast Cancer Surveillance Consortium Data Resource	01/01/2013-10/31/2014 Role: PI	10%
R03 CA150007 (PI: Hubbard) NCI Estimating the Cumulative Risk of a False-positive Screening Mammogram	06/01/2010-5/31/2012 Role: PI	20%

PUBLICATIONS and PRESENTATIONS

Publications

Peer-Reviewed Papers

*Denotes trainee mentored by Dr. Hubbard

†Denotes equal contribution

1. Cagle AJ and **Hubbard RA**. 2005. Cold-related cardiac mortality in King County, WA, USA, 1980-2001. *Annals of Human Biology*, 32(4): 525 - 537.
2. Sullivan J, **Hubbard RA**, Shepherd K, Trenga C, Liu L-JS, Koenig JQ, Chandler WL, Kaufman J. 2007. Effect of particulate matter on blood measures of inflammation and thrombosis in an elderly population. *BMC Environmental Health*. 6:3.
3. **Hubbard RA**, Inoue LYT, Fann JR. 2008. Modeling non-homogeneous Markov processes via time transformation. *Biometrics*. 64(3): 843 - 850.
4. **Hubbard RA**, Inoue LYT, Diehr P. 2009. Joint modeling of self-rated health and functional status. *Journal of the American Statistical Association*. 104(487): 873-885. PMID:PMC2819480
5. **Hubbard RA**, Miglioretti DL, Smith RA. 2010. Modelling the cumulative risk of a false-positive screening test. *Statistical Methods in Medical Research*. 19: 429-449. PMID: PMC2916076
6. Burn A, Herring S, **Hubbard RA**, Rafferty K, Duncan K, Lieberman D. 2010. Dietary consistency and midline sutures: A study in growing pigs. *Orthodontics & Craniofacial Research*. 13: 106 - 113.
7. Horne DJ, **Hubbard RA**, Narita M, Exarchos A, Park DR, Goss CH. 2010. Factors associated with mortality in patients with tuberculosis. *BMC Infectious Diseases*. 10:258.
8. Gill DP, Koepsell TD, **Hubbard RA**, Kukull WA. 2011. Risk of decline in functional activities in dementia with Lewy bodies and Alzheimer disease. *Alzheimer's Disease and Associated Disorders*. 25(1):17-23.
9. Fann JR, **Hubbard RA**, Alfano C, Roth-Roemer, S, Katon WJ, Syrjala KL. 2011. Pre - and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem cell transplantation. *Journal of Clinical Oncology*. 29(7): 895-901. PMID: PMC3068062.
10. **Hubbard RA** and Zhou XH. 2011. A non-homogeneous Markov regression model for mild cognitive impairment and Alzheimer's disease progression. *Journal of Applied Statistics*. 38(10): 2313-2326. PMID: PMC3299197.
11. Scholes D, **Hubbard RA**, Ichikawa L, LaCroix A, Spangler L, Beasley J, Reed S, Ott S. 2011. Oral contraceptive use and bone density change in adolescent and young adult women: a prospective study of age, hormone dose, and discontinuation. *Journal of Clinical Endocrinology & Metabolism*. 96(9):E1380-E1387.
12. Simon GE, Ding V, **Hubbard RA**, Fishman P, Ludman E, Morales L, Operskalski B, Savarino J. 2011. Early dropout from psychotherapy for depression with group- and network-model therapists. *Administration and Policy in Mental Health and Mental Health Services Research*. 39(6): 440-447. PMID: PMC3708590
13. **Hubbard RA**, Kerlikowske K, Flowers C, Yankaskas B, Zhu W, Miglioretti DL. 2011. The cumulative risk of a false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. *Annals of Internal Medicine*. 155: 481-492.
14. Kerlikowske K, **Hubbard RA**, Miglioretti D, Geller BM, Yankaskas BC, Lehman C, Taplin S, Sickles EA. 2011. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. *Annals of Internal Medicine*. 155: 493-502.
15. Fishman P, Ding V, **Hubbard RA**, Ludman E, Morales L, Operskalski B, Pabiniak C, Stewart C, Savarino J, Simon GE. 2012. Impact of cost sharing on initiation and continuation of psychotherapy for treatment of depression. *Health Services Research*. 47(4): 1561-1579. PMID: PMC3371095.
16. Chubak J, Anderson ML, Saunders KW, **Hubbard RA**, Tuzzio L, Liss D, Morales LS, Reid RJ. 2012. Predictors of one-year change in patient activation among older adults with diabetes and heart disease. *Journal of the American Geriatric Society*. 60(7):1316-21.
17. Chaudhari M, **Hubbard RA**, Inge R, Reid RJ, Newton KM, Spangler L, Barlow WE. 2012. Evaluating components of dental utilization among adults with diabetes and matched controls via hurdle models. *BMC Oral Health*. 12: 20.

18. Fenton JJ, Zhu W, Balch S, Smith-Bindman R, Lindfors K, **Hubbard RA**. 2012. External validation of Medicare claims codes for digital mammography and computer-aided detection. *Cancer Epidemiology, Biomarkers & Prevention*. 21(8): 1344-1347.
19. Yasmeen S, **Hubbard RA**, Miglioretti DM, Zhu W, Kerlikowske K, Geller BM, Onega T, Yankaskas BC, Romano P. 2012. Mammography use and breast cancer rates among older women with comorbidities. *Cancer Epidemiology, Biomarkers & Prevention*. 12(9):1510-1519.
20. **Hubbard RA**, Zhu W, Onega T, Fishman P, Henderson LM, Tosteson ANA, Buist D. 2012. Effects of digital mammography uptake on downstream breast-related care among older women. *Medical Care*. 50(12): 1053-1059.
21. Henderson LM, **Hubbard RA**, Onega T, Zhu W, Buist D, Fishman P, Tosteson ANA. 2012. Assessing healthcare use and cost consequences of a new screening modality: the case of digital mammography. *Medical Care*. 50(12): 1045-1052.
22. Imel ZE, **Hubbard RA**, Rutter C, Simon GE. 2012. Patient rated alliance as a measure of therapist performance in two clinical settings. *Journal of Consulting and Clinical Psychology*. 81(1):154-165.
23. Simon G, Peterson D, **Hubbard RA**. 2013. Is treatment adherence consistent across time, across treatments, and across diagnoses? *General Hospital Psychiatry*. 35(2):195-201. PMID: PMC3594411
24. *Ding VY, **Hubbard RA**, Rutter CM, Simon GE. 2013. Assessing the accuracy of profiling methods for identifying top providers: performance of mental health care providers. *Health Services and Outcomes Research Methodology*. 13(1): 1-17.
25. **Hubbard RA**, Miglioretti DL. 2013. A semi-parametric censoring bias model for estimating the cumulative risk of a false-positive screening test under dependent censoring. *Biometrics*. 69(1):245-53.
26. Goldman LE, Walker R, **Hubbard RA**, and Kerlikowske K. 2013. Timeliness of evaluation and loss to follow-up after abnormal mammography at mammography facilities serving vulnerable women. *Medical Care*. 51(4): 307-314.
27. Braithwaite D, Zhu W, **Hubbard RA**, O'Meara ES, Miglioretti DL, Geller B, Dittus K, Moore D, Wernli K, Mandelblatt J, Kerlikowske K for the BCSC. 2013. Screening outcomes in older U.S. women undergoing multiple mammograms in community practice: does interval, age or comorbidity score affect tumor characteristics or false positive rates? *Journal of the National Cancer Institute*. 105(5): 334-341.
28. Kerlikowske K, Zhu W, **Hubbard RA**, Geller B, Dittus K, Braithwaite D, Wernli K, Miglioretti DL, O'Meara ES. 2013. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. *JAMA Internal Medicine*. 173(9): 807-816.
29. **Hubbard RA**, Zhu W, Horbyluk R, Karliner L, Sprague B, Henderson L, Lee D, Onega T, Buist DSM, Sweet A. 2013. Timeliness and use of diagnostic imaging and biopsy following abnormal digital and film screening mammography. *Breast Cancer Research and Treatment*. 138(3):879-87.
30. Crane PK, Walker R, **Hubbard RA**, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn S, McCormick W, McCurry S, Bowen JD, Larson EB. 2013. Elevated glucose levels among those with and without diabetes as a risk factor for dementia: the Adult Changes in Thought Study. *New England Journal of Medicine*. 369(6):540-548.
31. Gray SL, Anderson ML, **Hubbard RA**, LaCroix A, Crane PK, Teri L, Bowen JD, McCormick W, McCurry SM, Larson, EB. 2013. Frailty and incident dementia in an older cohort. *Journal of Gerontology*. 68(9):1083-1090.
32. **Hubbard RA**, Johnson E, Hsia R, Rutter C. 2013. The cumulative risk of false-positive fecal occult blood test after 10 years of screening. *Cancer Epidemiology, Biomarkers & Prevention*. 22(9):1612-9.
33. Dittus K, Geller B, Weaver D, Kerlikowske K, Zhu W, **Hubbard RA**, Braithwaite D, O'Meara ES, Miglioretti DL. 2013. Impact of mammography screening interval on breast cancer characteristics of women with different body mass index. *Journal of General Internal Medicine*. 28(11):1454-62.
34. O'Meara ES, Zhu W, **Hubbard RA**, Braithwaite D, Kerlikowske K, Dittus K, Geller B, Wernli K, and Miglioretti D. 2013. Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. *Cancer*. 119(22): 3959-3967.
35. Gill DP, **Hubbard RA**, Koepsell TD, Borrie MJ, Petrella RJ, Knopman DS, Kukull WA. 2013. Differences in rate of functional decline across three dementia types. *Alzheimer's & Dementia*. 9(5): S63-S71.

36. Roman M, **Hubbard RA**, Sebuodegard S, Miglioretti DL, Castells X, Hofvind S. 2013. The cumulative risk of false positive results in the Norwegian Breast Cancer Screening Program: updated results. *Cancer*. 119(22), 3952-3958.
37. Dublin S, Anderson ML, Heckbert SR, **Hubbard RA**, Sonnen JA, Crane PK, Montine TJ, Larson EB. 2014. Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. *Journal of Gerontology, Series A: Biological Sciences/Medical Sciences*. 69(5):609-15.
38. Fenton J, Zhu W, Balch S, Smith-Bindman R, Lindfors K, Fishman P, **Hubbard RA**. 2014. Distinguishing screening from diagnostic mammograms using Medicare claims data. *Medical Care*. 52(7):e44-e51.
39. Stout NK, Lee SJ, Schechter CB, Alagoz O, Berry D, Buist DSM, Cevik M, Chisholm G, de Koning HJ, Huang H, **Hubbard RA**, Kerlikowske K, Munsell M, Tosteson ANA, Trentham-Dietz A, van Ravesteyn NT, Miglioretti DL, Mandelblatt JS. 2014. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. *Journal of the National Cancer Institute*. 106(6): dju092.
40. Henrikson NB, Anderson ML, **Hubbard RA**, Fishman P, Grossman D. 2014. Employee knowledge of value-based insurance design benefits. *American Journal of Preventive Medicine*. 47(2): 115-122.
41. Onega T, Weiss J, Goodrich M, Alford-Teaster J, Kerlikowske K, Buist DSM, Henderson LM, Wernli K, Virnig B, Tosteson ANA, DeMartini W, **Hubbard RA**. 2014. The influence of race/ethnicity and place of service on breast reconstruction for Medicare beneficiaries with mastectomy. *SpringerPlus*. 3(1): 1-9.
42. *Brenowitz WD, **Hubbard RA**, Crane PK, Gray SL, Zaslavsky O, Larson EB. 2014 Relationships between self-rated health and performance-based physical functioning in older adults: A population-based cohort study. *PLOS One*. 9(11):e111761.
43. Calip GS, Malone KE, Gralow JR, Stergachis A, **Hubbard RA**, Boudreau DM. 2014. Metabolic syndrome and outcomes in early stage breast cancer. *Breast Cancer Research & Treatment*. 148:363-377.
44. **Hubbard RA**, Chubak J, Rutter CM. 2014. Estimating screening test utilization using electronic health records data. *eGEMS (Generating Evidence & Methods to improve patient outcomes)*. 2(1):14. PMID: PMC4346157
45. Etzioni R, Xia J, **Hubbard RA**, Weiss N, Gulati R. 2014. A reality check for overdiagnosis estimates associated with breast cancer screening. *Journal of the National Cancer Institute*. 106(12): dju315.
46. Onega T, **Hubbard RA**, Hill D, Lee C, Haas J, Carlos HA, Alford-Teaster J, Bogart A, DeMartini W, Kerlikowske K, Virnig B, Buist D, Henderson L, Tosteson A. 2014. Geographic access to breast imaging for U.S. women. *Journal of the American College of Radiology*. 11(9): 874-882.
47. Wernli K, **Hubbard RA**, Johnson E, Chubak J, Kamineni A, Green BB, Rutter CM. 2014. Patterns of colorectal cancer screening uptake in newly-eligible men and women. *Cancer Epidemiology, Biomarkers & Prevention*. 23(7): 1230-1237.
48. Chubak J, **Hubbard RA**, Johnson E, Kamineni A, Rutter C. 2015. Assessing the effectiveness of a cancer screening test in the presence of another screening modality. *Journal of Medical Screening*. 22(2): 69-75.
49. **Hubbard RA**, Benjamin-Johnson R, Onega, T, Smith-Bindman R, Zhu W, Fenton JJ. 2015. Classification accuracy of Medicare claims-based methods for identifying providers failing to meet performance targets. *Statistics in Medicine*. 34(1):93-105.
50. Spangler L, Ichikawa L, **Hubbard RA**, Operskalski B, Ott S, Scholes D. 2015. Self-reported oral contraceptive use compared to automated pharmacy data in peri and early postmenopausal women. *Annals of Epidemiology*. 25(1): 55-59.
51. Calip GS, **Hubbard RA**, Stergachis A, Malone, KE, Gralow JR, Boudreau DM. 2015. Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. *Pharmacoepidemiology and Drug Safety*. 24(1): 75-85.
52. **Hubbard RA**, Zhu W, Balch S, Onega T, Fenton J. 2015. Identification of abnormal screening mammogram interpretation using Medicare claims data. *Health Services Research*. 50(1): 290-304.
53. Gray SL, Anderson ML, Dublin S, Hanlon JT, **Hubbard R**, Walker R, Yu O, Crane P, Larson EB. 2015. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Internal Medicine*. 175(3): 401-407.
54. Tom SE, **Hubbard RA**, Crane PK, Haneuse SJ, Bowen J, McCormick WC, McCurry S, Larson EB. 2015. Characterization of dementia and Alzheimer disease in an older population: Updated incidence and life expectancy with and without dementia. *American Journal of Public Health*. 105(2): 408-413. PMID: PMC4318311

55. *Lange JM, **Hubbard RA**, Inoue LYT, Minin VN. 2015. A joint model for multistate disease processes and random informative observation times, with applications to electronic medical records data. *Biometrics*. 71(1): 90-101.
56. Dublin S, Walker RL, Gray SL, **Hubbard RA**, Anderson ML, Yu O, Crane PK, Larson EB. 2015. Prescription opioids and risk of dementia or cognitive decline: a prospective cohort study. *Journal of the American Geriatric Society*. 63(8): 1519-1526.
57. Lee JM, Buist DSM, Houssami N, Lehman CD, Dowling E, Halpern EF, Gazelle GS, Henderson L, **Hubbard RA**. 2015. Five-year risk of interval invasive second breast cancer. *Journal of the National Cancer Institute*. 107(7): djv109.
58. Henderson LM, **Hubbard RA**, Sprague B, Zhu W, Kerlikowske K. 2015. Increased risk of developing breast cancer after a false positive screening mammogram. *Cancer Epidemiology, Biomarkers, and Prevention*. 24(12):1882-1889.
59. Lee CI, Bogart A, **Hubbard RA**, Obadina ET, Hill DA, Haas JS, Tosteson ANA, Alford-Teaster JA, Sprague BL, DeMartini WB, Lehman CD, Onega TL. 2015. Advanced breast imaging availability by screening facility characteristics. *Academic Radiology*. 22(7):846-52.
60. Jacobsen KK, Abraham L, O'Meara E, Buist DSM, **Hubbard RA**, Sprague B, Kerlikowske K, Euler-Chelpin MV, Njor S. 2015. Comparison of the cumulative false-positive risk of screening mammography in the United States and Denmark. *Cancer Epidemiology*. 39(4): 656-663.
61. **Hubbard RA**, Ripping TM, Chubak J, Broeders MJM, Miglioretti DL. 2015. Statistical methods for estimating the cumulative risk of screening mammography outcomes. *Cancer Epidemiology, Biomarkers & Prevention*. 25(3): 513-520. PMID: PMC4779749
62. Ripping TM, **Hubbard RA**, Otten JDM, den Heeten GJ, Verbeek ALM, Broeders MJM. 2016. Towards personalized screening: cumulative risk of breast cancer screening outcomes in women with and without a first-degree relative with a history of breast cancer. *International Journal of Cancer*. 138: 1619-1625.
63. Scholes D, LaCroix A, **Hubbard RA**, Ichikawa L, Spangler L, Operskalski B, Gell N, Ott SM. 2016. Oral contraceptive use and fracture risk around the menopausal transition. *Menopause*. 23(2): 166-174.
64. Henderson LM, Weiss J, **Hubbard RA**, O'Donoghue C, DeMartini WB, Buist DSM, Kerlikowske K, Goodrich M, Virnig B, Tosteson ANA, Lehman CD, Onega TL. 2016. Factors associated with preoperative magnetic resonance imaging use among Medicare beneficiaries with nonmetastatic breast cancer. *The Breast Journal*. 22(1): 24-34.
65. Miglioretti DL, Lange J, van Ravesteyn N, van den Broek JJ, Lee CI, Melnikow J, Fenton JJ, Kerlikowske K, Ritley D, de Koning HJ, **Hubbard RA**. 2016. Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. *Annals of Internal Medicine*. 164(4):205-214.
66. Fenton JJ, Onega T, Zhu W, Balch S, Smith-Bindman R, Henderson L, Sprague BL, Kerlikowske K, **Hubbard RA**. 2016. Validation of a Medicare claims-based algorithm for identifying breast cancers detected at screening mammography. *Medical Care*. 54(3):e15-e22. PMID: PMC4779749
67. Haas JS, Hill DA, Wellman RD, **Hubbard RA**, Lee CI, Wernli KJ, Stout NK, Tosteson AN, Henderson LM, Alford-Teaster JA, Onega TL. 2016. Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. *Cancer*. 122(4): 611-617. PMID: PMC4742376
68. Onega T, Tosteson AN, Weiss J, Alford-Teaster J, **Hubbard RA**, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, Wernli KJ, DeMartini WB, Virnig BA. 2016. Costs of diagnostic and preoperative workup with and without breast MRI in older women with a breast cancer diagnosis. *BMC Health Services Research*. 16(1): 76. PMID: PMC4769533
69. Lee CI, Bogart A, Germino J, Goldman LE, **Hubbard RA**, Haas JS, Hill DA, Tosteson ANA, Alford-Teaster JA, DeMartini WB, Lehman CD, Onega TL. 2016. Availability of advanced breast imaging at screening facilities serving vulnerable populations. *Journal of Medical Screening*. 23(1): 24-30. PMID: PMC4679713
70. Onega T, Lee CI, Alford-Teaster JA, Haas JS, Benkeser D, Tosteson ANA, Hill D, Shi X, Henderson L, Lange JM, **Hubbard RA**. 2016. Travel burden to breast MRI and utilization: are risk and sociodemographics related? *Journal of the American College of Radiology*. 13(6): 611-619.

71. Alford-Teaster JA, Lange J, **Hubbard RA**, Lee CI, Haas JS, Shi X, Carlos HA, Henderson L, Hill D, Tosteson ANA, Onega T. 2016. Is the closest facility the one actually used? An assessment of travel time estimation based on mammography facilities. *International Journal of Health Geographics*. 15:8.
72. Domingo L, Hofvind S, **Hubbard RA**, Roman M, Benkeser D, Sala M, Castells X. 2016. Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain. *European Radiology*. 26(8): 2520-2528.
73. Onega T, Weiss JE, Buist DSM, Tosteson ANA, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, Wernli KJ, DeMartini WB, Virnig BA, Bennett C, **Hubbard RA**. 2016. Breast MRI in the diagnostic and preoperative workup among Medicare beneficiaries with breast cancer. *Medical Care*. 54(7):719-724.
74. Gray SL, Dublin S, Yu O, Walker R, Anderson ML, **Hubbard RA**, Crane P, Larson EB. 2016. Benzodiazepine use and risk of incident dementia or cognitive decline. *BMJ*. 352:i90.
75. **Hubbard RA**, O'Meara E, Henderson L, Hill D, Lee CI, Wernli K, Tosteson ANA, Alford-Teaster J, Haas J, Sprague BL, Braithwaite D, Onega T. 2016. Multilevel factors associated with long-term adherence to screening mammography guidelines in older women. *Preventive Medicine*. 89:169-177.
76. **Hubbard RA**, Lange J, Zhang Y, Salim BA, Stroud JR, Inoue LYT. 2016. Using semi-Markov processes to study timeliness and tests used in the diagnostic evaluation of suspected breast cancer. *Statistics in Medicine*. 35(27): 4980-4993. PMID: PMC5096962
77. Marcus PM, Pashayan N, Church TR, Doria-Rose VP, Gould MK, **Hubbard RA**, Marrone M, Miglioretti DL, Pharoah PD, Pinsky PF, Rendle K, Robbins HA, Roberts MC, Rolland B, Schiffman M, Tiro JA, Zauber AG, Winn DM, Khoury MJ. 2016. Population-based precision cancer screening: a symposium on evidence, epidemiology, and next steps. *Cancer Epidemiology, Biomarkers & Prevention*. 25(11):1449-1455.
78. Goodrich ME, Weiss J, Onega T, Balch S, Buist SMB, Kerlikowske K, Henderson LM, **Hubbard RA**. 2016. The role of preoperative magnetic resonance imaging in the assessment and surgical treatment of interval and screen-detected breast cancer in older women. *The Breast Journal*. 22(6): 616-622.
79. Chubak J and **Hubbard RA**. 2016. Defining and measuring adherence to cancer screening. *Journal of Medical Screening*. 23(4):179-185.
80. Ozanne EM, Weiss J, Onega T, DeMartini W, Kerlikowske K, Buist DSM, Henderson L, **Hubbard RA**, Goodrich M, Tosteson ANA, Virnig B, O'Donoghue C. 2017. Locoregional treatment of breast cancer in women with and without preoperative MRI. *American Journal of Surgery*. 213(1):132-139.
81. Brenowitz W, Keene CD, Hawes SE, **Hubbard RA**, Longstreth W, Woltjer RL, Crane PK, Larson EB, Kukull W. 2017. Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic and community-based samples. *Neurobiology of Aging*. 53:83-92.
82. **Hubbard RA**, Johnson E, Chubak J, Wernli K, Kamineni A, Bogart T, Rutter CM. 2017. Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models. *Health Services and Outcomes Research Methodology*. 17(2):101-112. PMID:PMC5608281.
83. Brenowitz W, **Hubbard RA**, Keene CD, Hawes SE, Longstreth W, Kukull W. 2017. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. *Alzheimer's & Dementia*. 13(6):654-662.
84. Wernli KJ, Arao RF, **Hubbard RA**, Sprague B, Alford-Teaster JA, Haas JS, Henderson L, Hill D, Lee CI, Tosteson A, Onega T. 2017. Change in breast cancer screening intervals since the 2009 USPSTF guideline. *Journal of Women's Health*. 26(8):820-827.
85. Weissman GE, **Hubbard RA**, Kohn RA, Anesi GL, Manaker S, Prasad Kerlin M, Halpern SD. 2017. Validation of an administrative definition of ICU admission using revenue center codes. *Critical Care Medicine*. 45(8):e758-e762.
86. Dublin S, Walker RL, Gray SL, **Hubbard RA**, Anderson ML, Yu O, Montine TJ, Crane PK, Sonnen JA, Larson EB. 2017. Use of analgesics (opioids and nonsteroidal anti-inflammatory drugs) and dementia related neuropathology in a community-based autopsy cohort. *Journal of Alzheimer's Disease*. 58(2):435-448.
87. LaCroix AZ, **Hubbard RA**, Gray SL, Anderson ML, Crane PK, Sonnen J, Zaslavsky O, Larson EB. 2017. Trajectories of physical function prior to death and brain neuropathology in a community-based cohort: The ACT study. *BMC Geriatrics*. 17(1):258.

88. Brenowitz W, **Hubbard RA**, Keene CD, Hawes SE, Longstreth W, Kukull W. 2017. Mixed neuropathologies and associations with domain specific cognitive decline. *Neurology*. 89(17):1773-1781.
89. *Wang L, **Hubbard RA**, Walker R, Lee EB, Crane PK, Larson E. 2017. Assessing robustness of hazard ratio estimates to outcome misclassification in longitudinal panel studies with application to Alzheimer's disease. *PLOS One*. 12(12): e0190107.
90. Onega T, Weiss JE, Goodrich ME, Zhu W, DeMartini WB, Kerlikowske K, Ozanne E, Tosteson ANA, Henderson LM, Buist DSM, Wernli KJ, Herschorn SD, Hotaling E, O'Donoghue C, **Hubbard RA**. 2017. Relationship between preoperative breast MRI and surgical treatment of non-metastatic breast cancer. *Journal of Surgical Oncology*. 116(8):1008-1015.
91. Chubak J, **Hubbard RA**, Zhu W, Buist DSM, Onega T. 2017. An electronic health record-based algorithm to ascertain the date of second breast cancer events using automated data. *Medical Care*. 55(12):e81–e87.
92. Hill D, Haas JS, **Hubbard RA**, Wellman R, Lee CI, Alford-Teaster JA, Wernli K, Henderson L, Stout N, Tosteson ANA, Onega T. 2018. Breast cancer screening with magnetic resonance imaging in community practice. *Journal of General Internal Medicine*. 33(3):275-283.
93. Wan MT, Shin DB, **Hubbard RA**, Noe MH, Mehta NN, Gelfand JM. 2018. Psoriasis and risk of diabetes: A prospective population-based cohort study. *Journal of the American Academy of Dermatology*. 78(2):315-322.
94. †Huang J, †Duan R, **Hubbard RA**, Wu Y, Moore JH, Xu H, Chen Y. 2018. PIE: A prior knowledge guided integrated likelihood estimation method for bias reduction in association studies using electronic health records data. *Journal of the American Medical Informatics Association*. 25(3):345-352.
95. Catino A, **Hubbard RA**, Chirinos JA, Townsend R, Keefe S, Haas NB, Puznov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, ElAmm C, Lenihan D, Ky B. 2018. Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma. *Circulation*. 11:e004408.
96. *Chaiyachati K, Hom JK, **Hubbard RA**, Wong C, Grande D. 2018. Evaluating the association between the built environment and primary care access for new Medicaid enrollees in an urban environment using Walk and Transit Scores. *Preventive Medicine Reports*. 9:24-28.
97. Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, **Hubbard RA**, Kalbg RE, Mentere A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tying SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM. 2018. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: A randomized placebo-controlled trial. *Circulation: Cardiovascular Imaging*. 11(6):e007394.
98. *Chaiyachati KH, **Hubbard RA**, Yeager A, Mugo B, Lopez S, Asch E, Shi C, Shea JA, Rosin R, Grande D. 2018. Association of rideshare-based transportation services and missed primary care appointments. *JAMA Internal Medicine*. 178(3):383-389.
99. Sobrin L, Pan W, Stanwyck LK, **Hubbard RA**, Kempen J, VanderBeek BL. 2018. Association of hypovitaminosis D with increased risk of uveitis in a large health care claims database. *JAMA Ophthalmology*. 36(5):548-552.
100. *Bittermann T, **Hubbard RA**, Serper M, Lewis JD, Hohmann SF, VanWagner LB, Goldberg DS. 2018. Healthcare utilization after liver transplantation is highly variable both among centers and recipients. *American Journal of Transplantation*. 18(5):1197-1205.
101. *Chaiyachati K, **Hubbard RA**, Yeager A, Mugo B, Shea JA, Rosin R, Grande D. 2018. Rideshare-based medical transportation for Medicaid patients and primary care show rates: a difference-in-difference analysis of a pilot program. *Journal of General Internal Medicine*. 33(6):863-868.
102. Lee JM, Abraham L, Lam DL, Buist DSM, Kerlikowske K, Miglioretti DL, Houssami N, Lehman CD, Henderson LM, **Hubbard RA**. 2018. Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography. *Journal of Clinical Oncology*. 36(20):2070-2077.
103. Onega T, Zhu W, Weiss JE, Goodrich M, Tosteson ANA, DeMartini W, Virnig B, Henderson L, Buist DSM, Wernli K, Kerlikowske K, **Hubbard RA**. 2018. Preoperative breast MRI and mortality among older women with breast cancer. *Breast Cancer Research and Treatment*. 170(1):149-157.

104. Weissman GE, **Hubbard RA**, Ungar LH, Harhay MO, Greene CS, Himes BE, Halpern SD. 2018. Inclusion of unstructured clinical text improves early prediction of death or prolonged ICU stay. *Critical Care Medicine*. 46(7):1125-1132.
105. Henderson LM, **Hubbard RA**, Zhu W, Weiss J, Wernli K, Goodrich M, Kerlikowske K, DeMartini W, Ozanne E, Onega T. 2018. Pre-operative breast magnetic resonance imaging use by breast density and family history of breast cancer. *Journal of Women's Health*. 27(8):987-993.
106. Chubak J, Yu O, Ziebell R, Aiello Bowles EJ, Sterrett A, Fujii MM, Boggs J, Burnett-Hartman A, Boudreau DM, Chen L, Floyd J, Ritzwoller DP, **Hubbard RA**. 2018. Risk of colon cancer recurrence in relation to diabetes. *Cancer, Causes & Control*. 29:1093-1103.
107. Gray SL, Anderson ML, Hanlon JT, Dublin S, Walker R, **Hubbard RA**, Yu O, Montine TJ, Crane P, Sonnen JA, Larson EB. 2018. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy cohort. *Journal of Alzheimer's Disease*. 65:607-616.
108. Mantri S, Fullard M, Gray SL, Weintraub D, **Hubbard RA**, Hennessy S, Willis AW. 2019. Patterns of dementia treatment and frank prescribing errors in Parkinson disease. *JAMA Neurology*. 76(1):41-49.
109. Schapira MM, **Hubbard RA**, Seitz H, Conant E, Schnall M, Cappella J, Harrington T, Inge CA, Armstrong K. 2019. The impact of a risk-based breast cancer screening decision aid on initiation of screening among younger women: Report of a randomized trial. *Medical Decision Making Policy & Practice*. 4(1):1-13.
110. *Noe M, Shin DB, **Hubbard RA**, Hennessy S, Gelfand JM. 2019. Influenza vaccination rates in adults with psoriasis compared to adults with other chronic diseases. *Journal of Investigative Dermatology*. 139(2):473-475.
111. **Hubbard RA**, Huang J, Harton J, Oganisian A, Choi G, Utidjian L, Eneli I, Bailey LC, Chen Y. 2019. A Bayesian latent class approach for EHR-based phenotyping. *Statistics in Medicine*. 38: 74-87.
112. Greenblatt R, Zhao E, Henrickson S, Apter A, **Hubbard RA**, Himes BE. 2019. Factors associated with exacerbations among adults with asthma according to EHR data. *Asthma Research and Practice*. 5(1).
113. Chen Y, Wang J, Chubak J, **Hubbard RA**. 2019. Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrence. *Pharmacoepidemiology & Drug Safety*. 28(2): 264-268.
114. Borkar DS, Sobrin L, **Hubbard RA**, Kempen JH, VanderBeek BL. 2019. Techniques for improving ophthalmic studies performed on administrative databases. *Ophthalmic Epidemiology*. 26(3):47-149.
115. Noe MH, Rosenbach M, **Hubbard RA**, Cardones ARG, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Mostaghimi A, Musiek A, Ortega Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG. 2019. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. *JAMA Dermatology*. 155(4):448-454.
116. Bowles EJA, Yu O, Ziebell R, Chen L, Boudreau D, Ritzwoller DP, **Hubbard RA**, Boggs J, Burnett-Hartman A, Sterrett A, Fujii M, Chubak J. 2019. Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study. *BMC Cancer*. 19(1):270.
117. Pocobelli G, Yu O, Ziebell RA, Bowles EJA, Fujii MM, Sterret AT, Boggs JM, Chen L, Boudreau DM, Ritzwoller DP, **Hubbard RA**, Chubak JC. 2019. Use of antidepressants after colon cancer diagnosis and risk of recurrence. *Psycho-Oncology*. 28(4):750-758.
118. Demissei BG, Finkelman B, **Hubbard RA**, Smith AM, Narayan HK, Narayan V, Shah P, Waxman AJ, Domchek SM, Ky B. 2019. Cardiovascular function phenotypes in response to cardiotoxic breast cancer therapy. *Journal of the American College of Cardiology*. 73(2):248-249.
119. Feld E, Harton J, Meropol NJ, Adamson B, Cohen A, Parikh RB, Galsky MD, Narayan VK, Christodouleas J, Vaughn D, **Hubbard RA**, [†]Mamtani R. 2019. Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. *European Urology*. 76(4):524-532.
120. Demissei BG, Finkelman B, **Hubbard RA**, Zhang L, Smith AM, Sheline K, McDonald C, Narayan HK, Narayan V, Waxman AJ, Domchek SM, DeMichele A, Shah P, Clark AS, Bradbury A, Carver JR, Upshaw J, Armenian SH, Liu P, Ky B. 2019. Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy. *Cancer*. 125(16):2762-2771.

121. Chen L, Chubak J, Yu O, Pocobelli GP, Ziebell RA, Bowles EA, Fujii MM, Sterrett AT, Boggs JM, Ritzwoller DP, **Hubbard RA**, Boudreau DM. 2019. Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. *Cancer Causes & Control*. 30(12):1341-1350.
122. Chaayachati KH, Liao JM, Weissman GE, **Hubbard RA**, Morgan AU, Buehler A, Shea JA, Armstrong KA. 2019. Gender differences in retention and promotion among generalists who graduated from research-intensive fellowships. *Journal of Graduate Medical Education*. 11(5):535-542.
123. Ibáñez-Sanz G, Garcia M, Milà N, **Hubbard RA**, Vidal C, Binefa G, Benito L, Moreno V on behalf of the 'Adverse Effects on Colorectal Cancer Screening in Catalonia (EACC) Study' working group. 2019. False-positive results in a population-based colorectal screening programme: cumulative risk over seven biennial FOBT screening rounds. *Cancer Epidemiology, Biomarkers & Prevention*. 28(11):1909-1916.
124. Bittermann T, **Hubbard RA**, Lewis JD, Goldberg DS. 2019. The use of induction therapy in liver transplantation is highly variable and is associated with post-transplant outcomes. *American Journal of Transplantation*. 19(12):3319-3327.
125. Hong C, Duan R, Zeng L, **Hubbard RA**, Lumley T, Riley R, Chu H, Kimmel S, Chen Y. 2020. Galaxy plot: a new visualization tool of bivariate meta-analysis studies. *American Journal of Epidemiology*. 189(8):861-869.
126. Upshaw JN, Finkelman B, **Hubbard RA**, Smith AM, Narayan H, Arndt L, Domchek S, DeMichele A, Fox K, Shah P, Clark A, Bradbury A, Matro J, Adusumalli S, Carver JR, Ky B. 2020. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. *Journal of the American College of Cardiology: Cardiovascular Imaging*. 13(1):198-210.
127. Tong J, Huang J, Chubak J, Wang X, **Hubbard RA**, Chen Y. 2020. An augmented estimation procedure for EHR-based association studies accounting for differential misclassification. *Journal of the American Medical Informatics Association*. 27(2):244-253.
128. Demissei BG, **Hubbard RA**, Zhang L, Smith AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah P, Clark AS, Fox K, Matro J, Bradbury A, Knollman H, Getz K, Armenian S, Januzzi J, Tang WH, Liu P, Ky B. 2020. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. *Journal of the American Heart Association*. 9:e014708.
129. Bittermann T, **Hubbard RA**, Goldberg D. 2020. The proportion of Model for End-stage Liver Disease Sodium score attributable to creatinine independently predicts post-transplant survival and renal complications. *Clinical Transplantation*. 34: e13817.
130. Schapira MM, Williams M, Balch A, Baron RJ, Barrett P, Beveridge R, Collins T, Day SC, Fernandopulle R, Gilberg AM, Henley DE, Nguyen Howell A, Christine Laine C, Miller M, Ryu J, Schapira E, Schwarz DF, Schwarz M, Stevens J, Teisberg E, Yamaguchi K, **Hubbard RA**. 2020. Seeking consensus on the terminology of value-based transformation through use of a Delphi process. *Population Health Management*. 23(3):243-255.
131. **Hubbard RA**, Tong J, Duan R, Chen Y. 2020. Reducing bias due to outcome misclassification for epidemiologic studies using EHR-derived probabilistic phenotypes. *Epidemiology*. 31(4): 542-550.
132. Mahmud N, **Hubbard RA**, Kaplan DE, Taddei TH, Goldberg DS. 2020. Risk prediction scores for acute on chronic liver failure development and mortality. *Liver International*. 40(5):1159-1167.
133. Conant EF, Zuckerman S, McDonald ES, Weinstein SP, Korhonen K, Synnestvedt MB, Schnall MD, **Hubbard RA**. 2020. Five consecutive years of screening with digital breast tomosynthesis: Outcomes by screening year and round. *Radiology*. 295(2):285-293.
134. Xie S, [†]**Hubbard RA**, [†]Himes BE. 2020. Neighborhood-level measures of socioeconomic status are more correlated with individual-level measures in urban areas compared to less urban areas. *Annals of Epidemiology*. 43:37-43.
135. Kenyon CC, Maltenfort MG, **Hubbard RA**, Schinazi L, de Roos A, Henrickson S, Forrest CB. 2020. Variability in diagnosed asthma in young children in a large pediatric primary care network. *Academic Pediatrics*. 20(7):958-966.
136. Schinazi LH, Kenyon C, Melly S, Moore K, Zhao Y, **Hubbard RA**, Maltenfort M, De Roos A, Forrest C, Diez Roux A. 2020. Heavy precipitation and asthma exacerbation risk among children: A case-crossover study using electronic health records linked with geospatial data. *Environmental Research*. 188:109714.
137. Harrigan J, **Hubbard RA**, Thomas S, Riello RJ, Bange E, Mamtani M, Mamtani R. 2020. Association between US administration endorsement of hydroxychloroquine for COVID-19 and outpatient prescribing.

Journal of General Internal Medicine. 35:2826-2828.

138. Xiao KY, **Hubbard RA**, Kaplan DE, Taddei TT, Goldberg DS, Mahmud N. 2020. Models for acute on chronic liver failure development and mortality in a Veterans Affairs cohort. *Hepatology International.* 14:587-596.
139. Tom SE, Phadke M, Crane PL, **Hubbard RA**, Stern Y, Larson EB. 2020. Association of demographic and early-life socioeconomic factors by birth cohort with dementia incidence among US adults born between 1893 and 1949. *JAMA Network Open.* 3(7):e2011094.
140. Demissei BG, Adusumalli S, **Hubbard RA**, Denduluri S, Narayan V, Clark AS, Shah P, Knollman H, Getz KD, Aplenc R, Carver JR, Ky B. 2020. Cardiology involvement in patients with breast cancer treated with trastuzumab. *JACC: CardioOncology.* 2(2):179-189.
141. Mahmud N, **Hubbard RA**, Kaplan DE, Serper M. 2020. Declining cirrhosis hospitalizations in the wake of the COVID-19 pandemic: A national cohort study. *Gastroenterology.* 159(3):1134-1136.
142. Upshaw JN, **Hubbard RA**, Hu J, Brown J, Schmitz K, Ky B. 2020. Physical activity during and after breast cancer therapy and associations of baseline physical activity with changes in cardiac function by echocardiography. *Cancer Medicine.* 9(17):6122-6131.
143. De Roos A, Kenyon C, Zhao Y, **Hubbard RA**, Moore K, Melly S, Henrickson S, Maltenfort M, Schinasi LH, De Roos A, Forrest C, Diez Roux A. 2020. Ambient daily pollen levels in association with asthma exacerbation among children in Philadelphia, Pennsylvania. *Environment International.* 145:106138.
144. Sobrin L, Yu Y, Susarla G, Chan W, Xia T, Kempen JH, **Hubbard RA**, VanderBeek BL. 2020. Risk of non-infectious uveitis with female hormonal therapy in a large healthcare claims database. *Ophthalmology.* 127(11):1558-1566.
145. Huang W, Schinasi LH, Kenyon C, Moore K, Melly S, **Hubbard RA**, Zhao Y, Diez Roux AV, Forrest CB, Maltenfort M, J De Roos AJ. 2021. Effects of ambient air pollution on childhood asthma exacerbation in the Philadelphia metropolitan region, 2011 – 2014. *Environmental Research.* 197:110955.
146. Courts KA, **Hubbard RA**, Kersten HB, Klusaritz H. 2021. Stability of food insecurity status in paediatric primary care. *Public Health Nutrition.* 24(5):845-850.
147. Wang L, Schnell J, Small A, **Hubbard RA**, Moore J, Damrauer S, Chen J. 2021. Case contamination in electronic health records-based case-control studies. *Biometrics.* 77(1):67-77.
148. Sun L, Parikh RB, **Hubbard RA**, Cashy J, Takvorian SU, Vaughn DJ, Robinson KW, Narayan V, Ky B. 2021. Assessment and management of cardiovascular risk factors among US Veterans with prostate cancer initiating androgen deprivation therapy. *JAMA Network Open.* 4(2):e210070.
149. **Hubbard RA**, Xu J, Chen Y, Siegel R, Eneli I. 2021. Studying pediatric health outcomes with electronic health records using Bayesian clustering and trajectory analysis. *Journal of Biomedical Informatics.* 113:103654.
150. *Mahmud N, Fricker Z, **Hubbard RA**, Ioannou G, Lewis JD, Taddei TH, Rothstein KD, Serper M, Goldberg D, Kaplan DE. 2021. Risk prediction models for post-operative mortality in patients with cirrhosis: A retrospective cohort study. *Hepatology.* 73(1):204-218.
151. Doshi SD, Stotts MJ, **Hubbard RA**, Goldberg DS. 2021. The changing burden of alcoholic hepatitis: Rising incidence and associations with age, gender, race, and geography. *Digestive Diseases & Sciences.* 66:1707-1714.
152. *Harton J, Mamtani R, †Mitra N, †**Hubbard RA**. 2021. Bias reduction methods for propensity scores estimated from error-prone EHR-derived covariates. *Health Services and Outcomes Research Methodology.* 21(2):169-187.
153. Ellis DE, **Hubbard RA**, Willis AW, Zuppa AF, Zaoutis TE, Hennessy S. Comparative neurological safety of fluoroquinolones vs. therapeutic alternatives. 2021. *Pharmacoepidemiology & Drug Safety.* 30(6):797-805.
154. **Hubbard RA**, Lett E, Ho G, Chubak J. 2021. Characterizing bias due to differential exposure ascertainment in electronic health record data. *Health Services and Outcomes Research Methodology.* 21:309-323.
155. Zhu Y, **Hubbard RA**, Chubak J, Mitra N, Roy J. 2021. Core concepts in pharmacoepidemiology: Violations of the positivity assumption in the causal analysis of observational data: consequences and statistical approaches. *Pharmacoepidemiology & Drug Safety.* 30(11):1471-1485.

156. Weissman GE, Teeple S, Eneanya ND, **Hubbard RA**, Kangovi S. 2021. Effects of neighborhood-level data on performance and algorithmic equity of a model that predicts 30-day heart failure readmissions at an urban academic medical center. *Journal of Cardiac Failure*. 27(9):965-973.
157. Sobrin L, Yu Y, Han S, Susarla G, Kempen JH, **Hubbard RA**, VanderBeek BL. 2021. Decreased risk of non-infectious anterior uveitis with statin therapy in a large healthcare claims database. *Graefe's Archive for Clinical and Experimental Ophthalmology*. 259: 2783–2793.
158. Holmes J, Beinlich J, Boland M, Bowles K, Chen Y, Cook T, Demiris G, Draugelis M, Fluharty L, Gabriel P, Grundmeier R, Hanson C, Herman D, Himes B, **Hubbard RA**, Kahn C, Kim D, Koppel R, Long Q, Mirkovic N, Morris J, Mowery D, Ritchie M, Urbanowicz R, Moore J. 2021. Why is the electronic health record so challenging for research and clinical care? *Methods of Information in Medicine*. 60:32-48.
159. Parikh RB, Min EJ, Wileyto EP, Riaz F, Gross CP, Cohen RB, [†]**Hubbard RA**, [†]Long Q, [†]Mamtani R. 2021. Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers. *JAMA Oncology*. 7(12):1843-1850.
160. Xu J, Pratt K, Chaudhari M, Rohan H, **Hubbard RA**, Siegel R, Ihuoma E. 2021. On a different page! Perceptions on the onset, diagnosis, and management of type 2 diabetes among adolescent patients, parents, and physicians. *Global Pediatric Health*. 8: 2333794X211046430.
161. *Getz K, Mamtani R, **Hubbard RA**. 2021. Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights. *Journal of Biopharmaceutical Statistics*. 32(1):191-203.
162. Aysola J, Rewley J, **Hubbard RA**, Xu C, Schapira M. 2022. Primary care patient social networks and tobacco use: An observational study. *Journal of Primary Care and Community Health*. 13: 21501327211037894.
163. Sobrin L, Yu Y, Han S, Susarla G, Kempen JH, **Hubbard RA**, VanderBeek BL. 2022. Angiotensin converting enzyme-inhibitors and incidence of non-infectious uveitis in a large healthcare claims database. *Ophthalmic Epidemiology*. 29(1):25-30.
164. Martin JA, Crane-Droesch A, Lapite FC, Puhl JC, Kmiec T, Silvestri JA, Ungar LH, Kinosian BP, Himes BE, **Hubbard RA**, Diamond JM, Ahya V, Sims MW, Halpern SD, Weissman GE. 2022. Development and validation of a prediction model for actionable aspects of frailty in the text of clinicians' encounter notes. *Journal of the American Medical Informatics Association*. 21(9):109-119.
165. Yin Z, Tong J, Chen Y, **Hubbard RA**, Tang CY. 2022. A cost-effective chart review sampling design to account for phenotyping error in EHR data. *Journal of the American Medical Informatics Association*. 29(1):52-61.
166. Golmakani MK, **Hubbard RA**, Miglioretti DL. 2022. Non-homogeneous Markov chain for estimating the cumulative risk of multiple false-positive screening tests. *Biometrics*. 78(3)1244-1256.
167. Sobrin L, Yu Y, Han S, Susarla G, Kempen JH, **Hubbard RA**, VanderBeek BL. 2022. Risk of non-infectious uveitis with metformin therapy in a large healthcare claims database. *Ocular Immunology and Inflammation*. 30(6):1334-1340.
168. Ellis DE, **Hubbard RA**, Willis AW, Zuppa AF, Zaoutis TE, Hennessy S. 2022. Comparing LASSO and random forest models for predicting neurological dysfunction among fluoroquinolone users. *Pharmacoepidemiology and Drug Safety*. 31(4):393-403.
169. Liu X, **Hubbard RA**, Chubak J, Chen Y. 2022. SAT: a Surrogate Assisted two-wave case boosting sampling method, with application to EHR-based association studies. *Journal of the American Medical Informatics Association*. 29(5):918-27.
170. Ho T-QH, Bissell MCS, Kerlikowske K, **Hubbard RA**, Sprague BL, Lee CI, Tice JA, Rauscher GH, Tosteson ANA, Miglioretti DL for the Breast Cancer Surveillance Consortium. 2022. Cumulative probability of false positive results after 10 years of screening with digital breast tomosynthesis vs. digital mammography. *JAMA Network Open*. 5(3):e222440.
171. Ellis DE, **Hubbard RA**, Willis AW, Zuppa AF, Zaoutis TE, Hennessy S. 2022. Comparative risk of serious hypoglycemia among persons dispensed a fluoroquinolone versus a non-fluoroquinolone antibiotic. *Diabetes Research and Clinical Practice*. 185:109225.
172. Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Miksad RA, Calip GS, Ferrell W,

- Shulman LN, †Mamtani R, †**Hubbard RA**. 2022. Impact of the COVID-19 pandemic on treatment patterns for patients with metastatic solid cancer in the United States. *JNCI*. 114(4):571-8.
173. Nimgaonkar V, **Hubbard RA**, Carpenter EL, Mamtani R. 2022. Biomarker testing, treatment uptake, and survival among patients with urothelial cancer receiving gene-targeted therapy. *JAMA Oncology*. 8(7): 1070-1072.
174. Shah M, **Hubbard RA**, Marmarelis ME, Mamtani R, Hennessy S. 2022. Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti PD-(L)1 monotherapies in routine practice. *Pharmacoepidemiology & Drug Safety*. 31(10):1121-6.
175. Sun L, Brody R, Candelieri D, Anglin-Foote T, Lynch JA, Hausler R, Maxwell K, Damrauer S, Ojerholm E, Lukens JN, Cohen RB, Getz KD, **Hubbard RA**, Ky B. 2022. Association between up-front surgery and risk of stroke in United States veterans with oropharyngeal carcinoma. *JAMA Otolaryngology-Head & Neck Surgery*. 148(8):740-747.
176. Lo Re V, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, DeFor TA, Harrington LB, Hou L, Hennessy S, **Hubbard RA**, Kempner ME, Kuntz JL, McMahonill-Walraven CN, Mosley J, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM. 2022. Association of COVID-19 vs influenza with risk of arterial and venous thrombotic events among hospitalized patients. *JAMA*. 328(7):637-651.
177. Tan WK, Segal BD, Curtis MD, Baxi SS, Capra WB, Garrett-Mayer E, Hobbs BP, Hong DS, **Hubbard RA**, Sarkar S, Zhu J, Samant M. 2022. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations. *Contemporary Clinical Trials Communications*. 30:101000.
178. Schinasi LH, Kenyon CC, Yen Y-T, Moore K, Melly S, **Hubbard RA**, Maltenfort M, Forrest CB, Diez Roux AV, De Roost AJ. 2022. Associations between high ambient temperatures and asthma exacerbations among children in Philadelphia, PA: A time series analysis. *Occupational and Environmental Medicine*. 79(5):326-32.
179. †Ginestra JC, †Kohn R, **Hubbard RA**, Crane-Droesch A, Halpern SD, Prasad Kerlin M, Weissman GE. 2022. Association of unit census with delays in antimicrobial initiation among ward patients with hospital-acquired sepsis. *Annals of the American Thoracic Society*. 19(9):1525-33.
180. *Harton J, †Mitra N, †**Hubbard RA**. 2022. Informative presence bias in analyses of electronic health records-derived data: A cautionary note. *Journal of the American Medical Informatics Association*. 29(7):1191-99.
181. *Vader D, Parikh RB, Li H, Imai K, **Hubbard RA**, Mamtani R. 2022. Impact of label restriction on checkpoint-inhibitor use in bladder cancer and changes in mortality. *JNCI Cancer Spectrum*. 6(4):pkac050.
182. †Demissei BG, †*Vedage NA, **Hubbard RA**, Smith AM, Chung J, Getz KD, Lefebvre B, Getz K, Thavendiranathan P, Narayan HK, Ky B. 2022. Longitudinal right ventricular systolic function changes in breast cancer patients treated with cardiotoxic cancer therapy. *JACC: CardioOncology*. 4(4):552-4.
183. De Roost AJ, Kenyon CC, Yen Y-T, Moore K, Melly S, **Hubbard RA**, Maltenfort M, Forrest CB, Diez Roux AV, Schinasi LH. Does living near trees and other vegetation affect the contemporaneous odds of asthma exacerbation among pediatric asthma patients? *Journal of Urban Health*. 99:533–548.
184. Sprague BL, Chen S, Miglioretti DL, Gard CC, Tice JA, **Hubbard RA**, Bowles EA, Kaufman PA, Kerlikowske K. 2023. Cumulative six-year risk of screen-detected ductal carcinoma in situ by screening frequency. *JAMA Network Open*. 6(2):e230166.
185. Whitworth H, Clark H, **Hubbard RA**, Leonard CE, Witmer C, Raffini L. 2023. High rate of recurrent venous thromboembolism in children with unprovoked venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 21(1):47-56.
186. *Getz K, †**Hubbard RA**, †Linn K. 2023. Performance of multiple imputation using modern machine learning methods in electronic health records data. *Epidemiology*. 34(2):206-215.
187. *Harton J, Segal B, Mamtani R, †Mitra N, †**Hubbard RA**. 2023. Combining real-world and randomized control trial data using data-adaptive weighting via the on-trial score. *Statistics in Biopharmaceutical Research*. 15(2):408-420.
188. Sarma EA, Thompson MJ, Bowles EJA, Burnett-Hartman AN, Chen L, **Hubbard RA**, Yu O, Chubak J. 2023. Patient and tumor characteristics of screening-age adults diagnosed with screen-detected versus symptomatic colon cancer. *Colorectal Disease*. 24(11):1344-1351.

189. Parikh RB, **Hubbard RA**, Wang E, Royce TJ, Cohen AB, Clark AS, Mamtani R. 2023. Exposure to US cancer drugs with lack of confirmed benefit after US Federal Drug Administration accelerated approval. *JAMA Oncology*. 9(4):567-569.
190. Su Y-R, Buist DSM, Lee JM, Ichikawa L, Miglioretti D, Bowles E, Wernli KJ, Kerlikowske K, Tosteson A, Lowry KP, Henderson L, Sprague B, **Hubbard RA**. 2023. Performance of statistical and machine learning risk prediction models for breast cancer surveillance benefits and failures. *Cancer Epidemiology, Biomarkers & Prevention*. 32(4):561-571.
191. Lowry KP, Ichikawa L, **Hubbard RA**, Bowles EJA, Buist DSM, Henderson L, Kerlikowske K, Sprague BL, Specht J, Wernli KJ, Lee JM. 2023. Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status. *Cancer*. 129(8):1173-1182.
192. *Vader DY, Mamtani R, Li Y, Griffith SD, Calip GS, **Hubbard RA**. 2023. Inverse probability of treatment weighting and missingness in confounder data in EHR-based analyses: a comparison of three missing data approaches using plasmode simulation. *Epidemiology*. 34(4): 520–530.
193. Mamtani R, Zhang H, Paikh RB, Patel K, Li H, Imai K, **Hubbard RA**. 2023. Uptake of maintenance immunotherapy and changes in upstream treatment selection among patients with urothelial cancer. *JAMA Network Open*. 6(4):e238395.
194. Lo Re V, Dutcher SK, Connolly JG, Perez-Vilar S, Carbonari DM, Defor TA, Djibo DA, Harrington LB, Hou L, Hennessy S, **Hubbard RA**, Kempner ME, Kuntz JL, McMahill-Walraven CN, Mosley J, Pawloski PA, Petrone AB, Pishko AM, Rogers Driscoll M, Steiner CA, Zhou Y, Cocoros NM. 2023. Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with Covid-19 compared with influenza: retrospective cohort study. *BMJ Medicine*. 2(1): e000421
195. Whitworth H, Scobell R, **Hubbard RA**. Leonard CE, Witmer C, Raffini L. 2023. Outcomes in infants with unprovoked venous thromboembolism: A retrospective cohort study. *Research and Practice in Thrombosis and Haemostasis*. 7(4):100174.
196. *Shen J, **Hubbard RA**, Linn KA. 2023. Estimation and evaluation of individualized treatment rules following multiple imputation. *Statistics in Medicine*. 42(23):4236-4256.
197. Manik R, Grady CB, Elmore LC, Fieber JH, Freedman GM, Jankowitz RC, Tchou JC, Zhang JQ, **Hubbard RA**, Fayanju O. 2023. Temporal trends and factors associated with receipt of post-mastectomy radiation after neoadjuvant chemotherapy in women with cT3 breast cancer. *Annals of Surgical Oncology*. 30(11): 6506-6515.
198. †Ginestra JC, †Kohn R, **Hubbard RA**, Auriemma CL, Patel MS, Anesi GL, Halpern SD, Kerlin MP, Weissman GE. 2023. Association of time of day with delays in antimicrobial initiation among ward patients with hospital-onset sepsis. *Annals of the American Thoracic Society*. 20(9):1299-1308.
199. Schapira MM, **Hubbard RA**, Whittle J, Kaminstein D, Vachani A, Bastian LA, Chhatre S, Asan O, Kravetz JD, Prigge JM, Meline J, Clement JR, Clement BC, Frempong J, Fraenkel L. 2023. A randomized clinical trial of a lung cancer screening decision aid designed for the primary care setting. *JAMA Network Open*. 6(8):e2330452.
200. **Hubbard RA**, Pujol TA, Alhajar E, Edoh K, Martin ML. 2023. Identifying sources of disparities in surveillance mammography performance and personalized recommendations for supplemental breast imaging: A simulation study. *Cancer, Epidemiology, Biomarkers & Prevention*. 32 (11): 1531–1541.
201. Trentham-Dietz A, Corley D, del Vecchio N, Greenlee R, Haas JS, **Hubbard RA**, Hughes A, Kamineni A, Kim J, Kobrin S, Li C, Neslund-Dudas C, Tiro J. 2023. Filling data gaps for modeling cancer health disparities. *JNCI Monographs*. 62:246-254.
202. *Yuan C, †Linn KA, †**Hubbard RA**. 2023. Algorithmic fairness of machine learning models for Alzheimer's Disease progression. *JAMA Network Open*. 6(11): e2342203.
203. *Zhang H, Clark AS, **Hubbard RA**. 2024. A quantitative bias analysis approach to informative presence bias in electronic health records. *Epidemiology*. 35(3):349-358.
204. Luo C, Duan R, Edmondson M, Shi J, Maltenfort M, Morris J, Forrest C, **Hubbard RA**, Chen Y. 2024. Distributed proportional likelihood ratio model with application to data integration across clinical sites. *Annals of Applied Statistics*. 18(1):63-79.
205. †Demissei BG, †Ko K, Huang A, Lee DJ, Doucette AG, Smith AM, Wilcox NS, Reibel J, Sun L, Agarwal M, Haas NB, Hollis G, Shpilsky JE, Takvorian SU, Vaughn DJ, Chen J, **Hubbard RA**, Powell-Wiley T, Yancy C, Narayan V, Ky B. 2024. Social determinants of health mediate disparities in cardiovascular risk

- in men with prostate cancer treated with systemic androgen deprivation therapy. *JACC:CardioOncology*. 6(3):390-401.
206. Wang LS, Mamtani R, **Hubbard RA**. 2024. Comparing survival outcomes in trial- versus routine-care advanced urothelial cancer patients treated with immune checkpoint blockade. *Pharmacoepidemiology & Drug Safety*. 33(5):e5798.
 207. **Hubbard RA**, Su Y-R, Bowles EJA, Ichikawa L, Kerlikowske K, Lowry KP, Miglioretti DL, Tosteson ANA, Wernli K, Lee JM. 2024. Predicting five-year interval second breast cancer risk in women with prior breast cancer. *JNCI*. 116(6):929-937.
 208. Mamtani R, Tsingas K, Parikh RB, Elsouda D, Mucha L, Fuldeore, **Hubbard RA**. 2024. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer. *Urologic Oncology*. 42(6):177.e1-177.e4.
 209. †Lo Re V, †Cocoros NM, **Hubbard RA**, Dutcher SK, Newcomb CW, Connolly JG, Perez-Vilar S, Carbonari DM, Kempner ME, Petrone AB, Pishko AM, Rogers Driscoll M, Brash JT, Burnett S, Cohet C, Dahl M, DeFor TA, Delmestri A, Djibo DA, Duarte-Salles T, Harrington LB, Kampman M, Kuntz JL, Kurz X, Mercade-Besora N, Pawloski PA, Reijnbeek PR, Seager S, Steiner CA, Verhamme K, Wu F, Zhou Y, Burn E, Paterson JM, Prieto-Alhambra D. 2024. Risk of arterial and venous thrombotic events among patients with Covid-19: A multi-national collaboration of regulatory agencies from Canada, Europe, and United States. *Clinical Epidemiology*. 16:71-89.
 210. Te TT, Keenan BT, Veatch OJ, †**Hubbard RA**, †Pack AI. 2024. Enrichment and patterns of comorbidities in the electronic health record of patients with diagnosed obstructive sleep apnea. *Journal of Clinical Sleep Medicine*. 20(4):521-33.
 211. Shevach J, Lynch JA, Candelieri D, **Hubbard RA**, Alba PR, Glanz K, †Parikh RB, †Maxwell KN. 2024. Racial differences in germline genetic testing completion among males with pancreas, breast and metastatic prostate cancers. *Journal of the National Comprehensive Cancer Network*. 22(4):237-43.
 212. Tong J, Luo C, Sun Y, Duan R, Saine E, Lin L, Peng Y, Lu Y, Batra A, Pan A, Wang O, Li R, Marks-Anglin A, Yang Y, Zuo X, Liu Y, Bian J, Kimmel SE, Hamilton K, Cuker A, **Hubbard RA**, †Xu H, †Chen Y. 2023. Confidence score: A data-driven measure for inclusive systematic reviews considering unpublished preprints. *Journal of the American Medical Informatics Association*. 31(4):809-19.
 213. Manik R, Grady CB, Ginzberg SP, Edmonds CE, Conant EF, Hubbard RA, Fayanju OM. Manik R, Grady CB, Ginzberg SP, Edmonds CE, Conant EF, **Hubbard RA**, Fayanju OM. 2024. Racial disparities and strategies for improving equity in diagnostic follow-up for abnormal screening mammograms. *JCO Oncology Practice*. 20(10):1367-1375.
 214. Vigneswaran H, Eklund M, Discacciata A, Nordström T, **Hubbard RA**, Perlis N, Abern MA, Moreira DM, Eggener S, Yonover P, Chow A, Watts K, Liss M, Thoreson GR, Abreu AL, Sonn GA, Palsdottir T, Plyma A, Wiklund F, Grönberg H, Murphy AB, on behalf of the SEPTA STHLM3 Study Group. 2024. Stockholm3 in a multi-Ethnic cohort for ProstAte cancer detection (SEPTA): A prospective multicentered trial. *Journal of Clinical Oncology*. 42(32):3806-16.
 215. Rivera DR, Eckert JC, Rodriguez-Watson C, Lerro CC, **Hubbard RA**, Kushi LH, Lund JL, Schrag D, Wang SV, Wood WA, Lee J, Anyanwu C, Ghauri K, Winckler SC, Kluetz PG. 2024. The oncology QCARD initiative: Fostering efficient evaluation of initial real-world data proposals. *Pharmacoepidemiology & Drug Safety*. 33(11):e5818.
 216. Lu Y, Tong J, Chubak J, Lumley T, **Hubbard RA**, Xu H, Chen Y. 2024. Leveraging error-prone algorithm-derived phenotypes: Enhancing association studies for risk factors in EHR data. *Journal of Biomedical Informatics*. 157:104690.
 217. Miglioretti DL, Abraham L, Sprague BL, Kerlikowske K, Bissell MCS, Ho T-QH, Bowles EJA, Henderson LM, **Hubbard RA**, Lee CI, Rauscher GH, Tosteson ANA. 2024. Association between false-positive screening mammography results and return to screening in the Breast Cancer Surveillance Consortium cohort. *Annals of Internal Medicine*. 177(10):1297-307.
 218. Mamtani R, Ulloa-Perez E, Parikh RB, Patel K, Homet Moreno B, Ramamurthy C, Li H, **Hubbard RA**. 2024. Real-world uptake of enfortumab vedotin plus pembrolizumab after U.S. Food and Drug Administration approval among patients with advanced urothelial cancer. *European Urology*. 86(5):474-6.

219. *Yuan C, Duan J, Xu K, Tustison NJ, **Hubbard RA**, Linn KA. 2024. ReMiND: Recovery of missing neuroimaging using diffusion models with application to Alzheimer's Disease. *Imaging Neuroscience*. 2:1-14.
220. Gelfand JM, Armstrong AW, Lim HW, Feldman SR, Johnson SM, Claiborne WCC, Kalb RE, Jakus J, Mangold AR, Flowers RH, Bhutani T, Durkin J, Bagel J, Fretzin S, Sheehan MP, Krell J, Reeder M, Kaffenberger J, Kartono F, Takeshita J, Bridges AM, Fielding E, Nehal US, Schaecher KL, Howard LM, Eakin G, Báez S, Bishop BE, Fitzsimmons RC, Papadopoulos M, Song WB, Linn KA, **Hubbard RA**, Shin DB, Callis-Duffin K. 2024. Home-vs office-based narrowband UV-B phototherapy for patients with psoriasis: The LITE randomized clinical trial. *JAMA Dermatology*. 160(12):1320-1328.
221. Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, [†]**Hubbard RA**, [†]Mamtani R. 2024. Real-world impact of the platinum chemotherapy shortage on U.S. patients with advanced cancer. *JNCI*. djae307.
222. Lawson MB, Zhu W, Miglioretti DL, Onega T, Henderson LM, Rauscher GH, Kerlikowske K, Sprague BL, Bowles EJA, O'Meara ES, Tosteson ANA, diFlorio-Alexander RM, **Hubbard RA**, Lee JM, Lee CI. 2025. Disparities in standard-of-care, advanced, and same-day diagnostic services among patients with abnormal screening mammography. *Radiology*. 314(2):e241673.
223. Wolfova K, **Hubbard RA**, Cermakova P, Chang VW, Crane PK, LaCroix AZ, Larson EB, Tom SE. 2025. Number of children and risk of dementia. *Journal of Epidemiology and Community Health*. 79(4):280-287.
224. Lazarovich A, Vigneswaran H, Palsdottir T, Eklund M, Discacciati A, Nordström T, **Hubbard RA**, Perlis N, Abern MR, Moreira DM, Yonover P, Chow AK, Watts K, Liss MA, Thoreson GR, Abreu AL, Sonn GA, Plym A, Wiklund F, Grönberg H, Murphy AB, Eggener S on behalf of the SEPTA STHLM3 Study Group. 2025. A comparison of Stockholm3, serum biomarkers, and risk calculators to predict prostate cancer in a diverse cohort: Evaluation of the Stockholm3 Multi-Ethnic SEPTA Trial. *Journal of Urology*. 213(5):590-599.
225. Jung W, **Hubbard RA**, Smith AM, Ko K, Huang A, Wang J, Isaacs J, Zhang L, Liu PP, Chen Z, Shah PD, Mintzer D, Bhattacharya S, Knollman HM, Clark AS, Koropecjy-Cox D, Messiger M, Wilcox NS, Xia C, Narayan V, Upshaw JN, Armenian SH, Ky B. 2025. Risk-guided cardioprotection with carvedilol in racially diverse breast cancer patients (CCT Guide): A phase 1 randomized clinical trial. *Breast Cancer Research and Treatment*. 211: 293–305.
226. VanderBeek BL, Yu Y, Cardillo S, **Hubbard RA**. 2025 Twenty year trends in prevalence and incidence of diabetic retinal disease. *Ophthalmology*. 132(7): 767-774.
227. Weinstein EJ, Carbonari DM, Newcomb CW, Torgersen J, Smith SM, Brecker KL, Liu XS, Kostman JR, **Hubbard RA**, Baker JF, Zimmel BS, Leonard MB, Lo Re V. 2025. Abnormal trabecular and cortical bone microarchitecture in chronic Hepatitis C infection and associations with select inflammatory cytokines. *Open Forum Infectious Diseases*. 12(5):ofaf102.
228. Anglin A, Chen J, Luo C, **Hubbard RA**, Chen Y. 2025. Optimal surrogate-assisted sampling for cost-efficient validation of electronic health record outcomes. *Statistics in Medicine*. 44(10-12):e70095.
229. Ferrante ND, **Hubbard RA**, Weinfurter K, Mezina A, Newcomb C, Furth E, Bhattacharya D, Njei B, Taddei T, Singal A, Hoteit M, Park L, Kaplan D, Lo Re V. 2025. Validity of diagnostic codes and laboratory tests to identify cholangiocarcinoma. *Pharmacoepidemiology and Drug Safety*. 34(5):e70154.
230. Kurian M, Ferrell WJ, Ulloa Perez E, **Hubbard RA**, Joffe S, [†]Mamtani R, [†]Parikh RB, [†]Fernandez Lynch H. 2025. Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: A cross-sectional analysis. *BMJ Oncology*. 4(1):e000659.
231. *Shen J, Linn KA, **Hubbard RA**. 2025. Integrating misclassified EHR outcomes with validated outcomes from a non-probability sample. *Statistics in Medicine*. 44(15-17):e70127.
232. Parikh RB, Ulloa Perez E, Kurian M, **Hubbard RA**, Joffe S, Fernandez Lynch H, Mamtani R. 2025. Prescribing changes after accelerated vs. regular approval of oncology therapies. *JAMA Network Open*. 8(7):e2520726.
233. Schreibman A, Lactaoen K, Joo J, Gleeson PK, Weissman G, Apter AJ, **Hubbard RA**, Himes BE. Augmenting electronic health record data with social and environmental determinant of health measures to understand regional factors associated with asthma exacerbations. *PLOS Digital Health*. 4(6):e0000677.
234. Torgersen J, Newcomb CW, Carbonari DM, Smith SM, Brecker KL, Rajapakse CS, Jones BC, Cottrell C, Grewal R, Price JC, Baker JF, Kostman JR, Trooskin S, **Hubbard RA**, Zemel BS, Leonard MB, Lo Re V.

2025. Magnetic resonance evaluation of three-dimensional liver fat fraction by hepatitis C status and associations with inflammatory cytokines. *PLOS ONE*. 20(7):e0327668.
235. Ochoa-Allemant P, **Hubbard RA**, Kaplan DE, Serper M. 2025. Adverse liver outcomes, cardiovascular events, and mortality in patients with steatotic liver disease. *JAMA Internal Medicine*. 185(8):986-995.
236. Lee JM, Ichikawa L, Su Y-R, Noguchi N, **Hubbard RA**, Kerlikowske K, Specht J, O'Meara E, Henderson LM, Houssami N. 2025. Comparative accuracy of digital breast tomosynthesis and digital mammography for surveillance after breast cancer treatment. *Journal of the National Comprehensive Cancer Network*. 23(11):445-52.
237. Ochoa-Allemant P, **Hubbard RA**, Kaplan DE, Serper M. 2025. Cause-specific mortality in patients with steatotic liver disease: A nationwide cohort study. *Journal of Hepatology*. 83(4):860-869.
238. Schapira MM, Chhatre S, Dow PM, Leonard C, Groeneveld P, Prigge JM, Roberts CB, Meisel Z, Parikh R, Jayadevappa R, Paulson C, Krouse MD RS, Suda KJ, Kuma P, Muluk V, **Hubbard RA**. 2025. The impact of opioid use associated with curative intent cancer surgery on safe opioid prescribing practice among veterans: An observational study. *Cancer*. 131(18): e70009.
239. Tong J, Sun Y, **Hubbard RA**, Saine ME, Xu H, Zuo X, Lin L, Weng C, Schmid C, Kimmel SE, Umscheid CA, Cuker A, Chen Y. 2025. Incorporating preprints in systematic reviews: a preliminary study of a novel method for rapid evidence synthesis. *Journal of the American Medical Informatics Association*. 32(11):1654-63.
240. Gunn CM, Boyer N, Sheikh S, Lee JM, Woloshin S, Specht JM, **Hubbard RA**, Bowles E, Su Y-R, Tosteson ANA. 2025. Patient and physician perspectives on using risk prediction to support breast cancer surveillance decision-making. *Medical Decision Making*. 46(1):35-46.
241. Lo Re V, Carbonari DM, Newcomb CW, Torgersen J, Weinstein EJ, Smith SM, Brecker KL, Liu XS, Kostman JR, Trooskin S, **Hubbard RA**, Baker JF, Zemel BS, Leonard MB. 2025. Changes in bone microarchitecture and inflammatory cytokines after cure of chronic hepatitis C infection with direct-acting antiviral therapy. *Open Forum Infectious Diseases*. 12(9):ofaf571.
242. Xia C, Smith AM, Lefebvre B, Jamal FA, Armenian SH, Koropecykj-Cox D, Zhang L, Liu P, Landsburg D, Clark AS, Shah PD, **Hubbard RA**, Huang A, Golec S, Hewitt M, Wilcox NS, Chen Z, Rethy L, Jung W, Ko K, Narayan V, Martei Y, Januzzi JL, Felker GM, Ky B. 2025. Biomarker-guided cardioprotection for patients treated with anthracyclines: A randomized clinical. *JAMA Network Open*. 8(12): e2546201.
243. Kerlikowske K, Chen S, Sprague BL, Tice JA, Miglioretti DL, **Hubbard RA**. 2025. Effect of race and ethnicity on advanced breast cancer risk prediction model performance. *npj Digital Medicine*. 8:771.
244. Talathi R, **Hubbard RA**, Somasundar P, Espat NJ, Kwon S. 2026. STRASS 2 target trial emulation: Bridging the gap between trial efficacy and real-world effectiveness. *Surgery*. 194:110187.
245. *Shen J, Linn KA, Clark AS, Mamtani R, **Hubbard RA**. 2026. Missingness in eligibility criteria for target trial emulation in EHR with survival outcomes. *Statistics in Medicine*. 45(8-9):e70500.
246. Caplash S, Wahba J, Yu Y, Cardillo S, **Hubbard RA**, VanderBeek BL. Trends in prevalence and incidence of diabetic retinal disease in patients with Type 1 and Type 2 diabetes mellitus. 2026. *Journal of Diabetes and its Complications*. 40(6):109318.
247. *Vader DY, Shu D, **Hubbard RA**, Boge C, Sharova A, Downes K, Li Y. 2026. Informed presence in electronic health record data: illustrating bias and bias reduction approaches in longitudinal analyses. *Epidemiology. In press*.
248. Torgersen J, Newcomb CW, Carbonari DM, Smith SM, Brecker KL, Rajapakse CS, Jones BC, Cottrell C, Grewal R, Price JC, Baker JF, Kostman JR, Trooskin S, **Hubbard RA**, Zemel BS, Leonard MB, Lo Re III V. 2026. Changes in three-dimensional volumetric liver fat fraction after cure of chronic hepatitis C infection with direct-acting antivirals. *Open Forum Infectious Diseases. In press*.
249. Gómez LF, Lactaen K, Gleeson PK, Schreiberman A, Christie JD, Apter AJ, **Hubbard RA**, Weissman GE, Himes BE. 2026. Impact of the COVID-19 pandemic on adult asthma-related healthcare utilization. *Journal of Allergy and Clinical Immunology: Global. In press*.
250. Chang AY, Yu Y, Cardillo S, **Hubbard RA**, VanderBeek BL. 2026. Trends in prevalence and incidence of diabetic retinal disease across age cohorts. *Ophthalmology Retina. In press*.
251. Goblirsch TJ, Yu Y, Cardillo S, **Hubbard RA**, VanderBeek BL. 2026. Racial and ethnic differences in prevalence and incidence of diabetic retinal disease. *Retina. In press*.
252. Martei YM, Chen K, Obasohan M, Mamtani R, Aakhus E, Shulman LN, **Hubbard RA**, Clark A. 2026.

- Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer. *JNCI Cancer Spectrum*. In press.
253. Gunn CM, Boyer N, Sheikh S, Lee JM, Woloshin S, Specht JM, **Hubbard RA**, Bowles EJA, Tosteson ANA. 2026. Patient and physician-identified considerations for clinical implementation of a new risk-based prediction tool to guide surveillance mammography in breast cancer survivors. *JCO Oncology Practice*. In press.
254. Chen S, Kerlikowske K, Su YR, **Hubbard RA**, Gard CC, Tice JA, Sprague BL, Ahern TP, Miglioretti DL. 2026. Performance of statistical and machine learning risk prediction models for advanced breast cancers. *Cancer Epidemiology, Biomarkers & Prevention*. In press.

Book Chapters

1. Laird AE, **Hubbard RA**, Inoue LYT. 2015. Multi-state models for disease natural history. In: *Current Trends in Bayesian Methodology with Applications*. Chapman & Hall.
2. Broeders MJM, Ripping TM, **Hubbard RA**. 2016. Weighing the benefits and harms: Screening mammography in the balance. In: *Breast Cancer Screening*. Elsevier.
3. **Hubbard RA**, Harton J, Zhu W, Wang L, Chubak J. 2017. Accounting for differential error in time-to-event analyses using imperfect electronic health record-derived endpoints. In: *New Advances in Statistics and Data Science*. Springer.
4. **Hubbard RA**, Lou C, Himes B. 2021. The effective sample size of EHR-derived cohorts under biased sampling. In: *Modern Statistical Methods for Health Research*. Springer.

Other non-peer-reviewed scholarly publications

1. **Hubbard RA**. 2011. [Letter] RE: Modelling the cumulative risk of a false-positive screening test. *Statistical Methods in Medical Research*. 20(3):293-5
2. **Hubbard RA**, Kerlikowske K, Buist D, Yankaskas BC, for the Breast Cancer Surveillance Consortium. 2011. [Letter] Evaluation of breast cancer screening strategies must be based on comparisons of harms and benefits. *American Journal of Roentgenology*. 197:W793.
3. Kerlikowske K, **Hubbard RA**. 2011. [Letter] Comparative effectiveness of digital versus film-screen mammography. *Annals of Internal Medicine*. 156: 251.
4. Kerlikowske K, **Hubbard RA**, Tosteson ANA. 2014. [Letter] Higher mammography screening costs without appreciable clinical benefit: the case of digital mammography. *Journal of the National Cancer Institute*. 106(4): dju191.
5. **Hubbard RA**. 2015. [Invited commentary] US counties with higher rates of breast cancer screening have higher rates of breast cancer incidence with no concomitant decrease in breast cancer mortality. *BMJ Evidence Based Medicine*. 20(6): 201.
6. Miglioretti DL, Lange J, van Ravesteyn N, van den Broek JJ, Lee CI, Melnikow J, Kerlikowske K, Ritley D, de Koning HJ, **Hubbard RA**. 2015. [Report] Radiation-induced breast cancer and breast cancer death from mammography screening. Rockville, MD: Agency for Healthcare Research and Quality. AHRQ Publication No. 14-05201-EF-5. Available at: <http://www.uspreventiveservicestaskforce.org/Page/Document/modeling-report-radiation-induced-breast-cancer-and-breast-c/breast-cancer-screening1>
7. Gray SL, Anderson M, **Hubbard R**. 2015. [Letter] Anticholinergic use with incident dementia-reply. *JAMA Intern Med*. 175(9):1577. doi: 10.1001/jamainternmed.2015.2574.
8. Bradley CJ, Grossman DC, **Hubbard RA**, Ortega AN, Curry SJ. 2016. [Invited commentary] National Institutes of Health Pathways to Prevention Workshop: Integrated Interventions for Improving Total Worker Health®. *Annals of Internal Medicine*. 165(4):279-83.
9. Moore JH, Barnett I, Boland MR, Chen Y, Demiris G, Gonzalez-Hernandez G, Herman DS, Himes BE, **Hubbard RA**, Kim D, Mowery DL, Ritchie MD, Shen L, Urbanowicz R, Holmes JH. 2020. [Editorial] Ideas for how informaticians can get involved with COVID-19 research. *BioData Mining*. 13:1-16.

10. **Hubbard RA.** 2021. [Invited commentary] Commentary on Professor Austin Bradford Hill's Alfred Watson Memorial Lecture. *Statistics in Medicine.* 40(1):29-31.
11. VanderBeek BL, **Hubbard RA,** Ying GS. 2020. [Letter] Survival analysis vs. longitudinal modeling with multiple imputation, a false dichotomy. *JAMA Ophthalmology.* 39(5):588.
12. Mamtani R, Lund J, **Hubbard RA.** 2021. [Editorial] Considering the totality of evidence: Combining real-world data with clinical trial results to better inform decision-making. *Pharmacoeconomics & Drug Safety.* 30:814-816.
13. **Hubbard RA,** Gatsonis CA, Hogan JW, Hunter DJ, Normand S-LT, Troxel AB. 2024. [Perspective] “Target trial emulation” for observational studies – Potential and pitfalls. *New England Journal of Medicine.* 391:1975-1977.
14. Troxel AB, Gatsonis CA, Hogan JW, **Hubbard RA,** Hunter DJ, Normand S-LT. 2026. [Perspective] Statistics in Medicine – What’s in an Estimand? *New England Journal of Medicine.* 394(1):6-9.

Invited Presentations (last five years)

1. CANSI-NISS Health Data Science Workshop, *virtual presentation.* May 2021. Expediting Longitudinal Cohort Studies Using Electronic Health Records with Bayesian Clustering and Trajectory Analysis.
2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, *virtual presentation.* May 2021. Using EHR to Extend Understanding of Treatment Effectiveness Beyond Clinical Trials.
3. WNAR International Biometric Society, *virtual presentation.* June 2021. Meeting the Mandate of the 21st Century Cures Act: Overcoming the Challenges of Real World Data to Improve Cancer Care and Outcomes.
4. Sub-Saharan African Network International Biometric Society, *virtual presentation.* September 2021. An Introduction to Extraction and Analysis of EHR-derived Phenotypes.
5. Weill Cornell Medicine - Qatar, Population Health and Well-being Seminar Series, *virtual presentation.* September 2021. Considering the Totality of Evidence: Integrating Real World Data with Clinical Trial Data to Improve Decision Making.
6. New York University, Ethics and Real-World Evidence Working Group, *virtual presentation.* September 2021. Using EHR to Extend Understanding of Treatment Effectiveness Beyond Clinical Trials.
7. ASA Biopharmaceutical Statistics Section, Regulatory Industry Statistics Workshop, *virtual presentation.* September 2021. Principled Approaches to the Practical Challenges of Real-World Data.
8. University of Tennessee Health Science Center, Department of Preventive Medicine, *virtual presentation.* October 2021. Principled Approaches to the Practical Challenges of Real-World Data.
9. National Institute of Allergy and Infectious Diseases, Biostatistics Research Branch, *virtual presentation.* November 2021. Principled Approaches to the Practical Challenges of Real-World Data.
10. Michigan Data Science Institute, *virtual presentation.* January 2022. Leveraging Scientific Knowledge to Improve Learning from Real-World Data.
11. University of Michigan, Department of Biostatistics, *virtual presentation.* January 2022. Something Old, Something New: Classical and Modern Approaches to Addressing Missingness in Real-World Data.
12. Data Science Applied Research and Education Seminar Series, University of Toronto, Department of Biostatistics, *virtual presentation.* February 2022. Using Electronic Health Records to Accelerate Research Without Sacrificing Scientific Rigor.
13. School of Nursing, Case Western Reserve University, *virtual presentation.* February 2022. Extending Evidence from Clinical Trials to Underrepresented Populations Using Real-World Data.
14. Dana-Farber Cancer Center, Frontiers in Biostatistics, *virtual presentation.* March 2022. Considerations for Extracting Real-World Evidence from Real-World Data.
15. McGill University, Department of Biostatistics, Epidemiology and Occupational Health, *virtual presentation.* March 2022. Merging Content-area Knowledge and Biostatistical Principles to Transform Real-World Data into Real-World Evidence.
16. American Society for Preventive Oncology, Tucson, AZ. March 2022. Statistical Approaches for Bias Reduction in Cancer Outcomes Research Using Electronic Health Records Data.
17. University College London, Department of Statistical Science, *virtual presentation.* April 2022. Considerations for Deriving Timely and Valid Evidence from Electronic Health Records.

18. Women in Data Science Blacksburg, Virginia Tech, *virtual presentation*. April 2022. Accelerating Medical Research with Real-World Data and Scientific Insight.
19. Colorado School of Public Health, Department of Biostatistics & Informatics, *virtual presentation*. May 2022. Considerations for Deriving Timely and Valid Evidence from Electronic Health Records.
20. International Biometric Conference, Riga, Latvia. July 2022. Combining EHR and Clinical Trial Data to Improve Validity and Generalizability of Treatment Effectiveness Estimates.
21. Joint Statistical Meetings, Washington, DC. August 2022. Evaluation of Propensity Score-Calibration and Multiple Imputation for Missing Confounder Data in EHR-Based Comparative Effectiveness Research.
22. Penn Big Data in Biomedical and Health Data Science, Philadelphia, PA. September 2022. Deriving Complementary Evidence on Cancer Care and Outcomes from Clinical Trials and Real-World Data.
23. Institute of Healthcare Delivery Science, Icahn School of Medicine, Mt Sinai, *virtual presentation*. October 2022. Extending Evidence from Clinical Trials Using Real-World Data.
24. Stanford Biomedical Informatics Research Colloquia, Stanford University, *virtual presentation*. October 2022. Leveraging Modern Statistical and Machine Learning Approaches to Address Missingness in Real-World Data.
25. Modern Statistical and Machine Learning Methods for Big Data, University of Michigan, Ann Arbor, Michigan. October 2022. Too Big to Fail: Bias, Fairness and Ethics of Conducting Medical Research in the Era of Big Data.
26. Biostatistics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, *virtual presentation*. October 2022. Advancing Cancer Research Using Modern Approaches to Missingness in Real-World Data.
27. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. January 2023. Fair and Valid Learning with RWD.
28. Inaugural Black History/Heritage Month Statistics Colloquium Lecture, Rice University, Houston, Texas. March 2023. Advancing Timely and Valid Medical Research with Real-World Data and Medical Science.
29. Kaiser Permanente Washington Health Research Institute, Seattle, WA. April 2023. Something Old, Something New: Classical and Modern Approaches to Missingness in Real-World Data.
30. Plenary session, International Society for Pharmacoeconomics and Outcomes Research, Boston, MA. May 2023. Informative Presence Bias in Analyses of EHR Data.
31. Washington Statistical Society Gertrude M Cox Lecture, Washington, DC. June 2023. Too Big to Fail: Bias, Fairness and Ethics of Conducting Medical Research in the Era of Big Data.
32. Keynote presentation, Michigan Big Data Summer Institute, Ann Arbor, MI. July 2023. Advancing Timely and Valid Medical Research with Real-World Data and Medical Science.
33. Joint Statistical Meetings, Toronto, ON. August 2023. Expanding the Evidence-Base for Medically Underserved Populations by Integrating Evidence from RCTs And Electronic Health Records.
34. Sentinel Innovation and Methods Seminar Series, *virtual presentation*. August 2023. Leveraging Missing Data and Measurement Error Approaches in Propensity Score-Based Analyses of Real-World Data.
35. Center on Population & Aging Science. University of Texas Austin, Austin, TX. September 2023. Opportunities and Challenges for Advancing Health Equity Through Electronic Health Records-based Research.
36. Department of Biostatistics & Computational Biology, University of Rochester, Rochester, NY. September 2023. Accounting for Differential Data Quality in Analyses of Data from Electronic Health Records.
37. Women in Statistics and Data Science, Bellevue, WA. October 2023. Identifying and Mitigating Disparities in Health Care Use and Outcomes Arising Due to Differential EHR Data Quality.
38. Institute for Mathematical Statistics-Asia Pacific Rim Meeting, Melbourne, Australia. January 2024. Classical And Machine Learning Imputation Approaches to Missing Data in Electronic Health Records-Based Studies.
39. Department of Mathematics & Statistics, University of Vermont, Burlington, VT. February 2024. Opportunities and Challenges for Advancing Health Equity Through Electronic Health Records-based Research.
40. ENAR International Biometric Society, Baltimore, MD. March 2024. Addressing Informed Presence Bias in the Analysis of EHR Data.

41. Fred Hutchison Cancer Center and Department of Biostatistics, University of Washington Joint Seminar, Seattle, WA. April 2024. Safeguarding Medically Underserved Populations in EHR-Based Research Subject to Informed Presence Bias.
42. Board on Healthcare Services, National Academies of Science, Engineering & Medicine, Washington, DC. April 2024. Data Integration to Address Generalizability and Data Quality Challenges in AD Research.
43. Ethical Need and Questions for Digital Twins, National Academies of Science, Engineering & Medicine, *virtual presentation*. May 2024. Disparities in Personalized Medicine Arising from Differential Data Quality.
44. Division of Quantitative Sciences, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD. May 2024. Safeguarding Medically Underserved Populations in EHR-Based Research Subject to Informed Presence Bias.
45. Joint Statistical Meetings, Portland, OR. August 2024. Statistical Challenges in Development of Equitable Approaches to Risk-Guided Cancer Screening Using EHR Data.
46. Department of Data Science, University of Mississippi Medical Center, *virtual presentation*. September 2024. Not so fast: Accelerating precision medicine with EHR data while safeguarding medically underserved populations.
47. Chair's Invited Lecture, Department of Biostatistics, Brown University, Providence, RI. September 2024. Context is king: Addressing informed presence bias in EHR-based research.
48. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Quebec, Canada. October 2024. Context is king: Addressing informed presence bias in EHR-based research.
49. International Day of Women in Statistics and Data Science, *virtual presentation*. October 2024. Context is queen: Advancing EHR-based research through our lived experience with medicine, science and data.
50. Science & Society Lecture, Department of Mathematics, Statistics and Computer Science, Macalester College, St Paul, MN. October 2024. Not so fast: Accelerating medical research with big data while safeguarding vulnerable populations and research rigor.
51. Department of Biostatistics and Data Science, Wake Forest University, Winston-Salem, NC. November 2024. Not so fast: Accelerating precision medicine with EHR data while safeguarding medically underserved populations.
52. Department of Biomedical Informatics, Columbia University, *virtual presentation*. December 2024. Safeguarding Medically Underserved Populations in EHR-Based Research.
53. Department of Biostatistics, School of Global Public Health, New York University, New York, NY. February 2025. Unraveling the threads of informed presence bias and health inequities in EHR research.
54. ENAR International Biometric Society, New Orleans, LA. March 2025. Using contextual knowledge to understand and address selection bias in EHR-based analyses.
55. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA. April 2025. Informed presence bias in EHR analysis: Contextual thinking for better inference.
56. Presidential invited address, Statistical Society of Canada Annual Meeting, Saskatoon, Saskatchewan, Canada. May 2025. Data-driven research: Advancing equity with integrity.
57. Plenary speaker, International Breast Density and Cancer Risk Assessment Workshop, Lihue, HI. June 2025. Sources of disparities in EHR-based research on breast cancer survivorship and surveillance.
58. Joint Statistical Meetings, Nashville, TN. August 2025. Considering the Totality of the Evidence: Integrating EHR and Primary Data Collection to Improve Medical Decision Making.
59. International Day of Women in Statistics and Data Science, *virtual presentation*. October 2025. Prediction Algorithms and Persistence: The Long Road to a Simple Solution.
60. ECOG-ACRIN Comis Translational Science Symposium, Philadelphia, PA. October 2025. External Controls from Real-World Data in Therapeutic Trials.
61. Department of Biostatistics, Johns Hopkins University, Baltimore, MD. November 2025. The Brave New World of Real-World Data.
62. Department of Health Services, Policy & Practice, Brown University, Providence, RI. January 2026. The Brave New World of Real-World Data.
63. Department of Biostatistics, Yale University, New Haven, CT. January 2026. The Brave New World of Real-World Data.

64. ENAR International Biometric Society, Indianapolis, IN. March 2026. Re-imagining Control Arms in the Age of Real-World Data.
65. Meredith Kilgore Endowed Lecture, COERE Methods Symposium, University of Alabama at Birmingham, Birmingham, AL. April 2026. Causal Inference with Real-World Data: The Evolution of Rigorous Research.
66. American Association for Cancer Research, San Diego, CA. April 2026. Integrating EHR-derived real-world data into therapeutic trials: Design and analysis strategies for hybrid control designs.